Acrylonitrile induction of rodent neoplasia: Potential mechanism of action and relevance to humans

Tetyana Kobets1, Michael J Latropoulos1 and Gary M Williams1

Abstract
Acrylonitrile, an industrial chemical, is a multisite carcinogen in rats and mice, producing tumors in four tissues with barrier function, that is, brain, forestomach, Zymbal’s gland, and Harderian gland. To assess mechanism(s) of action (MoA) for induction of neoplasia and to evaluate whether the findings in rodents are indicative of human hazard, data on the potential key effects produced by acrylonitrile in the four rodent target tissues of carcinogenicity were evaluated. A notable finding was depletion of glutathione in various organs, including two target tissues, the brain, and forestomach, suggesting that this effect could be a critical initiating event. An additional combination of oxidative DNA damage and cytotoxic effects of acrylonitrile and its metabolites, cyanide, and 2-cyanoethylene oxide, could initiate pro-inflammatory signaling and sustained cell and tissue injury, leading to compensatory cell proliferation and neoplastic development. The in vivo DNA-binding and genotoxicity of acrylonitrile has been studied in several target tissues with no compelling positive results. Thus, while some mutagenic effects were reported in acrylonitrile-exposed rodents, data to determine whether this mutagenicity stems from direct DNA reactivity of acrylonitrile are insufficient. Accordingly, the induction of tumors in rodents is consistent primarily with a non-genotoxic MoA, although a contribution from weak mutagenicity cannot be ruled out. Mechanistic data to support conclusions regarding human hazard from acrylonitrile exposure is weak. Comparison of metabolism of acrylonitrile between rodents and humans provide little support for human hazard. Three of the tissues affected in bioassays (forestomach, Zymbal’s gland, and Harderian gland) are present only in rodents, while the brain is anatomically different between rodents and humans, diminishing relevance of tumor induction in these tissues to human hazard. Extensive epidemiological data has not revealed causation of human cancer by acrylonitrile.

Keywords
Acrylonitrile rodent carcinogenicity, genotoxicity, glutathione depletion, cytotoxicity, oxidative damage

Introduction
Acrylonitrile, also known as vinyl cyanide, is an organic compound widely used as a monomer in industry for the synthesis of polymers and resins.1,2 Human exposure to acrylonitrile occurs mainly through inhalation in occupational settings or through cigarette smoke, exposures by oral and dermal routes are uncommon.1,2 Small amounts of acrylonitrile can be also released from the combustion of plant matter (e.g., biomass).3

The carcinogenicity of acrylonitrile in rodents has been extensively investigated and large-scale epidemiological studies have been conducted. While in humans most epidemiological studies produced no consistent findings of
increased cancer risk associated with acrylonitrile exposure,\textsuperscript{4–12} in rodent carcinogenicity bioassays, acrylonitrile produced tumors in multiple sites, including the brain, mammary gland, and Zymbal’s (auditory sebaceous tissue) gland of rats, forestomach of rats and mice, and Harderian (secretory orbital tissue) gland of mice. Increases in brain tumors observed in several acrylonitrile bioassays in male and female rats of two strains,\textsuperscript{13,14} although not in mice,\textsuperscript{15,16} led to a concern that acrylonitrile could be a central nervous system carcinogen in humans.

Previously, Meek et al.\textsuperscript{17} reviewed the evidence relating to key events in acrylonitrile rodent brain carcinogenicity and whether the mechanisms of acrylonitrile carcinogenicity in rodents are plausible in humans. They concluded that the data available at that time were not sufficient to support a consensus view on a plausible mode of action for acrylonitrile-induced rat brain tumors. The subsequent finding that these tumors in rats were microglial/histiocytic in origin (i.e., malignant microgliomas),\textsuperscript{18} as well as the availability of new mechanistic studies,\textsuperscript{19–24} prompted the present re-evaluation of potential mechanism(s) of action (MoA(s)) of acrylonitrile and relevance to humans.

This review of available data was undertaken to establish MoA(s) for the principal rodent neoplasia findings in four target tissues. The assessment leads to the hypothesis that the MoA for tumor increases elicited by acrylonitrile in forestomach, brain, Zymbal’s gland, and Harderian gland could, in part, involve cytotoxic effects to target tissues by the parent compound and its metabolites, cyanide, and 2-cyanoethyleneoxide (CEO) due to rapid depletion of glutathione (GSH) in target organs and liver. In the brain, cytotoxicity was accompanied by oxidative stress. Those effects are postulated to initiate a cascade of events leading to neoplasms in the four vulnerable barrier tissues, which are susceptible to tumorigenesis.\textsuperscript{25} It is possible, however, that more than one MoA can be involved in carcinogenicity produced by acrylonitrile in rodents, and definitive mechanistic data for a MoA were found to be lacking.

\textbf{Methods}

\textit{Literature search}

A search of the published literature was conducted for combinations of the following terms: acrylonitrile, vinyl cyanide, toxicity, single-dose, repeat dose, acute, chronic, long-term, reproductive, developmental, carcinogenicity, tumorigenicity, cancer, neoplasia, tumor, malignancy, forestomach, brain, Zymbal’s gland, Harderian gland, epidemiologic, biomonitoring, genotoxicity, in vitro, in vivo, binding, macromolecules, protein, DNA, damage, adducts, strand breaks, mutagenicity, clastogenicity, chromosome aberrations, Ames, micronucleus, mouse lymphoma, sister chromatid exchange, study, test, assay, oxidative damage, oxidative stress, mitochondrial damage, inflammation, glutathione, depletion, cytotoxicity, immunosuppression, animal, rat, mouse, human, toxicokinetics, pharmacokinetics, physiological based pharmacokinetic modeling and simulation (PBPK), mechanisms, mode of action, mechanisms of action, metabolism, absorption, uptake, distribution, elimination, excretion, dose, and dose-response, using the following databases:

1. Pub Med (https://www.ncbi.nlm.nih.gov/pubmed) is a free source premier database for biomedical literature indexed in the National Library of Medicine MEDLINE database. It contains over 30 million citations from over 5000 current biomedical journals. Coverage range: 1950s to present.
2. EMBASE (https://www.embase.com) is a comprehensive index of the biomedical and pharmacological literature. It includes citations from over 8400 journals, 1000 conferences, and 70 countries. Coverage range: 1947 to present.
3. Web of Science (http://apps.webofknowledge.com) provides access to current and retrospective abstracts and cited references found in 3700 journals covering more than 100 disciplines. Coverage range: 1996 to present.
4. Science Direct (http://www.sciencedirect.com) is a web collection of 161 full-text scientific journals and e-books. Coverage range: 1995 to present.
5. ChemIDplus database (https://chem.nlm.nih.gov) provides access to the structure and properties for chemical substances cited in National Library of Medicine database. The database contains more than 400,000 chemical records.

In addition, safety profiles for acrylonitrile prepared by regulatory organizations including European Chemicals Agency,\textsuperscript{3} European Chemicals Bureau,\textsuperscript{1} IARC\textsuperscript{2,26,27} Occupational Safety and Health Administration,\textsuperscript{28} and US EPA\textsuperscript{29,30} were reviewed. Publications written in languages other than English were excluded.

\textit{MoA analyses}

To structure the analysis of the reviewed literature, the evidence for key characteristics of carcinogens (Table 1) proposed by IARC\textsuperscript{31} to support conclusions regarding potential human hazard from exposure to carcinogens was evaluated taking into consideration chemokinetic and chemodynamic factors in order to assess potential mechanisms of carcinogenicity and to evaluate whether the findings in rodents are plausible in humans.

To address some concerns of the robustness of the IARC approach,\textsuperscript{32} a weight of evidence (WoE) evaluation for the
key events of hypothesized MoA(s) based on evolved Bradford Hill considerations33 (Table 1) was also applied.

**Dose-response assessment for carcinogenicity findings**

In order to characterize carcinogenic potency of acrylonitrile, tumor findings in target organs in rodent chronic bioassays were analyzed using the Benchmark dose (BMD) approach. BMD modeling was performed using the US EPA BMDS software version 3.0, according to the guidance in the software manual. A multistage-cancer model was used to calculate the BMDL (indicative of a 10% increase in tumor incidence over the control) for each data set. This model was selected for the present analyses since it also calculates a cancer slope factor (CSF). This cancer potency factor is an upper-bound estimate of the increase in cancer risk after a lifetime exposure of 70 years to a chemical by ingestion or inhalation. The fit of the model is given in Supplemental Figures 1–4. The BMDL and BMDU refer to the lower and upper bounds of a two-sided 95% confidence interval for calculated BMD10.

---

**Table 1. Considerations for hypothesized mechanism of action (MoA) analyses.**

| Key characteristics of carcinogens defined by IARCa |
|-----------------------------------------------------|
| It is electrophilic or can be metabolically activated |
| It is genotoxic                                      |
| It alters DNA repair or causes genomic instability  |
| It induces epigenetic alterations                    |
| It induces oxidative stress                          |
| It induces chronic inflammation                      |
| It is immunosuppressive                              |
| It modulates receptor-mediated effects               |
| It causes immortalization                           |
| It alters cell proliferation, cell death, or nutrient supply |

**Evolved Bradford Hill weight of evidence considerationsb**

- Biological concordance: does the hypothesized MoA conflict with broader biological knowledge?
- How well established is the MoA in the wider biological database?

- Essentiality of key events:
- is the sequence of events reversible if dosing is stopped or a key event prevented?
- Are the key events observed at doses below or similar to those associated with the adverse effect?
- Are the key events observed in hypothesized order?
- Is the occurrence of the end (adverse) effect less than that for the preceding key events?

- Consistency:
- Is the pattern of effects across species/strains/organisms/test systems what would be expected?

- Analogy: would the MoA be anticipated based on broader chemical-specific knowledge?

aAdapted from Smith et al.31
bAdapted from Meek et al.33

---

**Results**

**Summary of acrylonitrile toxicity and carcinogenicity in humans**

Humans exhibit acute toxicity to acrylonitrile. Thus, in workers, acute inhalational and/or dermal exposure to acrylonitrile at various concentrations above 5 ppm (10.9 mg/m³) was reported to result in irritation of eyes and nose, cyanosis, and neurological symptoms (headache, dizziness, fatigue, nausea, and vomiting).23 These symptoms were reversible. Cases of occupational contact dermatitis have been reported after dermal exposure to acrylonitrile.34

A considerable body of epidemiological data has not revealed evidence of human cancer risk from acrylonitrile exposure.5–12 While a recent retrospective study by the US National Cancer Institute on mortality of workers exposed to acrylonitrile reported a statistically significant (p for trend = .05) association between acrylonitrile exposure and lung cancer, as well as a possible association with increased mortality from bladder cancer and pneumonitis.15 Findings from comprehensive meta-analysis did not support increased risk of lung cancer among acrylonitrile-exposed workers.4
The International Agency for Research on Cancer (IARC) conducted several evaluations of acrylonitrile. In the first evaluation, IARC concluded that acrylonitrile “should be regarded as if it was carcinogenic to humans.” Later the carcinogenic risk of acrylonitrile to humans was assessed as “probable” (Group 2A), based on the limited evidence in epidemiologic studies and sufficient evidence for carcinogenicity to animals. In the latest IARC evaluation, acrylonitrile was downgraded to a “possible” human carcinogen, Group 2B, due to inadequate evidence for the carcinogenicity of this compound in humans based on additional epidemiological studies in occupationally exposed populations. The National Toxicology Program (NTP) listed acrylonitrile as a “reasonably anticipated to be a human carcinogen” based on sufficient evidence of carcinogenicity in experimental animals. The Environmental Protection Agency (EPA) classifies acrylonitrile as a “probable human carcinogen” (Group B1), based on the limited evidence of carcinogenicity in humans.

**Experimental carcinogenicity data and summary of neoplastic findings**

Acrylonitrile was reported to produce tumors in multiple sites in rats and mice in a dose-related fashion in several chronic rodent studies, conducted with various protocols, utilizing several modes of acrylonitrile administration. Six of these studies of greater than 18 months in duration have been validated and accepted by regulatory agencies, and hence, were selected as the dataset for the current analyses. Five out of six studies were conducted in rats, with acrylonitrile administered in drinking water, by oral gavage or inhalation. One study was conducted in mice dosed with acrylonitrile by oral gavage. Findings in several other chronic bioassays conducted with acrylonitrile are also briefly discussed.

Indicators of systemic stress associated with general toxic effects of acrylonitrile were reported in the rodent bioassays. These included increased mortality rates, decrease in food and water consumption, and consequent reduction in body weight gain, as well as mild anemia, evidenced by reduction in hematocrit, hemoglobin, and erythrocyte count levels. Hematological changes were attributed to either blood loss from ulcerated tumors or poor nutrition (“nutritional anemia”) of the animals and generalized stress from acrylonitrile exposure, rather than bone marrow toxicity.

Of the three modes of acrylonitrile administration to rats, intake in drinking water in both SD and F344 strains most severely impacted survival, especially in female rats, which were dosed with higher doses (up to 17% greater) compared to males. An increase in mortality rates began at 10 and 16 months at 300 ppm and at 12 and 20 months at 100 ppm in both female and male rats, respectively, and at 18 months in both sexes at 35 ppm in the drinking water. The remainder of acrylonitrile-dosed rats of both sexes were terminated at 22 months. Reduction in survival was similar for the same oral dosages between the SD and F344 strains of rats. With gavage administration, increased mortality was evident in rats of both sexes at 8.5 (male)/10.8 (female) mg/kg/day beginning at 14 months, until study termination at 20 months. In B6C3F1 mice, which also were dosed with acrylonitrile by oral gavage, the high dose (14.3 mg/kg/day) produced significant reduction in survival in both sexes (males greater than females), after approximately 1 year of dosing. In the rat inhalation study, mortality was increased at 80 ppm, starting at 6 months in males, and 10 months in females, until termination of the study at 22 months.

Species-specific differences in target tissues for acrylonitrile-induced carcinogenicity were observed between rats and mice, with exception of the common occurrence of forestomach neoplasia in both species. In all rat bioassays, forestomach, brain, and Zymbal’s gland were common target organs, regardless of the route of administration. In the mouse gavage study, forestomach neoplasia as well as Harderian gland tumors were observed. Hyperplastic changes in target organs were often observed in both rats and mice at carcinogenic dosages of acrylonitrile or one dose level below the carcinogenic doses, suggesting that these events were associated with neoplasia. Tumors in the small intestine, mammary gland, and tongue were also observed in several rat bioassays, but these tumors were sex-specific and, thus, were not considered for the current analyses. In female mice, neoplasms of the ovary and lung may have been related to administration of acrylonitrile, however, association with exposure was considered equivocal due to a lack of dose-response; thus, these findings were also excluded.

**Studies in rats**

In the studies with acrylonitrile administration in the drinking water to SD rats, incidences of forestomach and Zymbal’s gland neoplasia were significantly increased in both sexes in groups dosed with 100 ppm and above, while Zymbal’s gland tumors were also observed in females at 35 ppm. Brain neoplasms were present in dosed groups in both sexes at 35 ppm and above.

Statistically significant increases in the incidences of squamous carcinomas of Zymbal’s gland and a trend towards an increase of forestomach papillomas were also observed in SD rats that received 500 ppm of acrylonitrile in drinking water. The small group size (20 rats per group) limited the power of the study. At 500 ppm, rats exhibited higher mortality rates, a trend towards a decrease in water consumption, and a slower increase in body weight gain. No tumor increases in other organs were reported.
Table 2. Systemic toxicity-associated findings in rodent carcinogenicity studies of acrylonitrile.

| Strain, route of administration and duration | Dosage, mg/kg/d | Change (% incidence) | Hematologic changes |
|--------------------------------------------|-----------------|----------------------|---------------------|
| SD rats, drinking water, 22 (M) or 19 (F) months | 3.4 4.4 | ↓ F  (35–44%) | ↓ F  (25–27%) | - |
| F344 rats, drinking water, 24 (M) or 23 (F) months | 0.1 0.1 | N/C  | N/C  | N/C - |
| B6C3F1 mice, oral gavage, 5 days per week, 18 (M) or 22 (F) months | 2.5 | N/C  | N/R  | N/C - |
| 1) Quast 2002 | 10 | ↓ (30–40%) | ↑ F  (6%) | N/C - |
| 2) Johannsen and Levinskas 2000a | 0.3 4.4 | ↓ F  (14%) | ↑ M  (15%) | F  |
| 3) Johannsen and Levinskas 2002b | 8.4 10.9 | ↓ (40–60%) | ↓ (11–13%) | ↓ (11–13%) |
| 4) Johannsen and Levinskas 2002a | 0.8 1.3 | ↓ M  (10%) | N/C  | N/C - |
| 5) Quast et al. 1980 | 2.5 3.7 | ↓ (20–40%) | N/C  | N/C - |
| 6) Ghanayem et al. 2002; NTP 2001 | 8.4 10.9 | ↓ (40–60%) | ↓ (11–13%) | ↓ (11–13%) + F |

F344 rats were more susceptible to acrylonitrile tumorigenicity compared to SD rats. Thus, acrylonitrile administered in drinking water produced a significant increase in the incidences of forestomach neoplasia in F344 males at 3 ppm and above (with exception of 100 ppm), and in F344 females at 30 ppm. Brain tumors in both sexes and Zymbal’s gland tumors in males were significantly induced by 30 ppm and above, Zymbal’s gland tumors in females were induced by 10 ppm and above (Tables 4 and 7). The low survival of rats in the highest dose group (100 ppm) after 14 months of the study possibly affected statistical analyses. In a study to investigate the nature of the brain tumors, F344 rats of both sexes were administered acrylonitrile in drinking water at 100 and 500 ppm for 12–18 months. At both dose levels, acrylonitrile produced an increase in incidences of brain tumors, primarily observed in the cortex. While cells adjacent to the lesions were reactive astrocytes, negative staining of the tumors for glial fibrillary acidic protein (GFAP) microscopically, as well as ultrastructural evidence of no glial filaments, indicated that the neoplastic cells were different in origin (i.e., not astrocytes). An increase in incidences of Zymbal’s gland tumors and forestomach and subcutaneous papillomas was also observed in acrylonitrile-dosed rats. In addition to carcinogenicity, rats that received acrylonitrile exhibited signs of systemic and neurotoxicity from 12 to 18 months (i.e., until termination). Similar to the outcomes described above for F344 rats, acrylonitrile administered by oral gavage to SD rats at 100 ppm (equivalent to male and female doses of 8 and 10.7 mg/kg of acrylonitrile in drinking water per day, respectively) produced a significant increase in tumor incidences in three target organs (forestomach, brain, and Zymbal’s gland) in rats in both sexes (Tables 5 and 7). In an inhalation study of acrylonitrile in SD rats, no increase in forestomach tumor incidences was observed, while brain and Zymbal’s gland neoplasms were present in both sexes at the highest dose of 80 ppm (equivalent dose of 173.6 mg/m³ per day). Brain tumors were also observed at 20 ppm in
Table 3. Percent incidence of pertinent non-neoplastic and neoplastic findings in Sprague-Dawley rats dosed with acrylonitrile in drinking water for 2 years.

| Microscopic finding                  | Sex   | Acrylonitrile dosage$^{a,b}$ |       |       |       |       |       |
|--------------------------------------|-------|-----------------------------|-------|-------|-------|-------|-------|
|                                      | M     | 0 ppm$^{a,b}$ 0.1 mg/kg/d    | 0.09 mg/kg/d 3.4 mg/kg/d | 8.5 mg/kg/d 8 mg/kg/d$^d$ | 21.3 mg/kg/d |
|                                      | F     | 0.02 mg/kg/d 0.58 mg/kg/d   | 1.46 mg/kg/d 1.36 mg/kg/d | 3.62 mg/kg/d |
| Forestomach hyperplasia/hyperkeratosis| M     | 19% 77% 90% 32%            | 92%* 91%* 94%*          |       |       |
|                                      | F     | 25% 81% 63% 48%*          | 85%* 83%* 98%          |       |       |
| Forestomach papilloma/carcinoma      | M     | 0 3% 3% 4%              | 48%* 12% 81%*          |       |       |
|                                      | F     | 1.3% 1% 2% 2%             | 25%* 7%* 63%*          |       |       |
| Glial cell proliferation             | M     | 0 0 0 1%             | 2% 7%* 33%*           |       |       |
|                                      | F     | 0 0 0 1%             | 2% 7%* 33%*           |       |       |
| Brain astrocytomas$^d$               | M     | 13% 2% 3% 17%*         | 40%* 24% 48%*         |       |       |
|                                      | F     | 1.3% 0 1% 35%*         | 46%* 33%* 50%*        |       |       |
| Zymbal's gland hyperplasia$^e$       | M     | 3% 1% 0 9%           | 6% 20%* 33%*         |       |       |
|                                      | F     | 1.3% 1% 0 10%*        | 19%* 12%* 38%*        |       |       |

*, statistically significant (p < .05) compared to in-study control values for both pairwise and trend parameters; F, female; M, male.

$^a$Quast 2002.$^{38}$
$^b$Johannsen and Leviskas 2002a.$^{37}$
$^c$HED, human equivalent dose.$^{29}$
$^d$Now considered to be malignant microglial tumors.$^{18}$
$^e$Palpable at 24 months.

Table 4. Percent incidence of pertinent non-neoplastic and neoplastic findings in Fischer 344 rats dosed with acrylonitrile in drinking water for 2 years.

| Microscopic finding                  | Sex   | Acrylonitrile dosage$^a$ |       |       |       |       |       |
|--------------------------------------|-------|--------------------------|-------|-------|-------|-------|-------|
|                                      | M     | 0 ppm 0.1 mg/kg/d        | 0.09 mg/kg/d 3.4 mg/kg/d | 8.5 mg/kg/d 8 mg/kg/d$^d$ | 21.3 mg/kg/d |
|                                      | F     | 0.02 mg/kg/d 0.58 mg/kg/d | 1.46 mg/kg/d 1.36 mg/kg/d | 3.62 mg/kg/d |
| Forestomach hyperplasia/hyperkeratosis| M     | 6% 3% 19%* 13%*         | 17%* 9%* 5%*          |       |       |
|                                      | F     | 2% 2% 16%* 24%*         | 13%* 5%* 2%*          |       |       |
| Forestomach papilloma/carcinoma      | M     | 0 1% 4%* 4%*           | 4%* 4%* 1%*          |       |       |
|                                      | F     | 0–1% 1% 2% 2%           | 4%* 4%* 2%*          |       |       |
| Gliosis                              | M     | 1% 0 0 0              | 0 0 1%           |       |       |
|                                      | F     | 0 0 0 0              | 1% 0 0           |       |       |
| Brain astrocytomas$^d$               | M     | 0–2% 2% 1% 2%         | 10%* 21%* 23%*    |       |       |
|                                      | F     | 0–1% 1% 2% 4%*         | 6%* 23%* 12%*      |       |       |
| Zymbal's gland papilloma/adenoma/carcinoma | M     | 0–2% 1% 0 2         | 7%* 17%* 12%*     |       |       |
|                                      | F     | 0 0 2% 4%*            | 5%* 12%*          |       |       |

*, statistically significant (p < .05) compared to in-study control values for both pairwise and trend parameters; F, female; M, male.

$^a$Johannsen and Leviskas 2002b.$^{14}$
$^b$Marked increase in mortality.
$^c$HED, human equivalent dose.$^{29}$
$^d$Now considered to be malignant microglial tumors.$^{18}$
female rats (43.4 mg/m³ per day) (Tables 5 and 7). The authors also reported inflammatory changes in the respiratory epithelium of the nasal turbinates at both dose levels, with less severe changes observed at 20 ppm. These findings were considered to result from irritation produced by acrylonitrile. Acute suppurative pneumonia observed in the rats administered 80 ppm of acrylonitrile was interpreted to be related to stress from acrylonitrile exposure.

In a study in SD rats, no increase in tumor incidences was observed after oral gavage with acrylonitrile at 5 mg/kg bodyweight for 52 weeks. In contrast, in inhalation studies, statistically significant, but not dose-related, increases in the total number of animals with tumors were observed in rats of both sexes exposed to acrylonitrile at the dose range from 5 to 40 ppm for 52 weeks. Slight, not significant increases were observed in the incidences of “encephalic glyomas,” although, the numbers were within the historical control range. When administered at 60 ppm for 104 weeks to breeders and offspring rats, acrylonitrile produced an increase in

---

**Table 5.** Percent incidence of pertinent neoplastic findings in Sprague-Dawley rats dosed with acrylonitrile by oral gavage and by inhalation for 2 years.

| Microscopic finding                        | Sex | Acrylonitrile dosage |
|--------------------------------------------|-----|----------------------|
|                                            |     | 0 ppm    | 1 ppm    | 100 ppm  | 0 ppm   | 20 ppm   | 80 ppm   |
|                                            |     | 0 mg/kg/d | 0.1 mg/kg/d | 10 mg/kg/d | 0 mg/kg/d | 2 mg/kg/d | 9 mg/kg/d |
|                                            | M   | 0 mg/kg/d | 0 mg/kg/d | 0 mg/kg/d | 0 mg/kg/d | 0 mg/kg/d | 0 mg/kg/d |
|                                            | F   | 0.1 mg/kg/d | 0.1 mg/kg/d | 0.1 mg/kg/d | 0.1 mg/kg/d | 0.1 mg/kg/d | 0.1 mg/kg/d |
| Forestomach hyperplasia/hyperkeratosis     | M   | 79%       | 69%       | 81%*      | 8%       | 7%       | 16%       |
|                                            | F   | 80%       | 84%       | 90%*      | 2%       | 3%       | 7%        |
| Forestomach papilloma/carcinoma            | M   | 2%        | 6%        | 40%*      | 1%       | 2%       | 5%        |
|                                            | F   | 2%        | 4%        | 17%*      | 0        | 0        | 1%        |
| Glial cell proliferation                    | M   | N/R       | N/R       | N/R       | 0        | 0        | 4%        |
|                                            | F   | 0        | 0        | 0        | 4%        | 4%        |
| Brain astrocytomas                          | M   | 2%        | 0        | 16%*      | 0        | 4%       | 15%*      |
|                                            | F   | 1%        | 2%        | 17%*      | 0        | 4%*      | 16%*      |
| Zymbal’s gland adenoma/carcinoma            | M   | 1%        | 1%        | 16%*      | 2%       | 4%       | 11%*      |
|                                            | F   | 1%        | 0        | 15%*      | 0        | 1%       | 11%*      |

*, statistically significant (p < .05) compared to in-study control values for both pairwise and trend parameters; F, female; M, male; N/R, not reported.

**Table 6.** Percent incidence of pertinent non-neoplastic and neoplastic findings in B6C3F1 mice dosed with acrylonitrile and delivered by oral gavage for 2 years.

| Microscopic finding                        | Sex | Acrylonitrile dosage |
|--------------------------------------------|-----|----------------------|
|                                            |     | 0 mg/kg/d | 1.8 mg/kg/d | 7.1 mg/kg/d | 14.3 mg/kg/d |
|                                            | M   | 0 mg/kg/d | 1.8 mg/kg/d | 7.1 mg/kg/d | 14.3 mg/kg/d |
|                                            | F   | 0 mg/kg/d | 1.8 mg/kg/d | 7.1 mg/kg/d | 14.3 mg/kg/d |
| Forestomach hyperplasia                    | M   | 4         | 8%         | 16%*       | 18%*       |
|                                            | F   | 4         | 4%         | 10%        | 14%*       |
| Forestomach papilloma/carcinoma            | M   | 6         | 8%         | 52%*       | 64%*       |
|                                            | F   | 6         | 14%        | 50%*       | 58%*       |
| Harderian gland hyperplasia                | M   | 2         | 8%         | 14%*       | 8%         |
|                                            | F   | 10        | 8%         | 12%        | 16%        |
| Harderian gland adenoma/carcinoma          | M   | 12        | 32%*       | 54%*       | 60%*       |
|                                            | F   | 22        | 20%        | 52%*       | 50%*       |

*, statistically significant (p < .05) compared to in-study control values for both pairwise and trend parameters; F, female; M, male.

**Table 5.** Percent incidence of pertinent neoplastic findings in Sprague-Dawley rats dosed with acrylonitrile by oral gavage and by inhalation for 2 years.

| Acrylonitrile dosage |
|----------------------|
| Sex | 0 ppm | 1 ppm | 100 ppm | 0 ppm | 20 ppm | 80 ppm |
| M   | 0 mg/kg/d | 0.1 mg/kg/d | 10 mg/kg/d | 0 mg/kg/d | 2 mg/kg/d | 9 mg/kg/d |
| F   | 0.1 mg/kg/d | 0.1 mg/kg/d | 0.1 mg/kg/d | 0.1 mg/kg/d | 0.1 mg/kg/d | 0.1 mg/kg/d |
| Forestomach hyperplasia/hyperkeratosis | M | 79% | 69% | 81%* | 8% | 7% | 16% |
| F | 80% | 84% | 90%* | 2% | 3% | 7% |
| Forestomach papilloma/carcinoma | M | 2% | 6% | 40%* | 1% | 2% | 5% |
| F | 2% | 4% | 17%* | 0 | 0 | 1% |
| Glial cell proliferation | M | N/R | N/R | N/R | 0 | 0 | 4% |
| F | 0 | 0 | 0 | 4% | 4% |
| Brain astrocytomas | M | 2% | 0 | 16%* | 0 | 4% | 15%* |
| F | 1% | 2% | 17%* | 0 | 4%* | 16%* |
| Zymbal’s gland adenoma/carcinoma | M | 1% | 1% | 16%* | 2% | 4% | 11%* |
| F | 1% | 0 | 15%* | 0 | 1% | 11%* |

*, statistically significant (p < .05) compared to in-study control values for both pairwise and trend parameters; F, female; M, male.

**Table 6.** Percent incidence of pertinent non-neoplastic and neoplastic findings in B6C3F1 mice dosed with acrylonitrile and delivered by oral gavage for 2 years.

| Acrylonitrile dosage |
|----------------------|
| Sex | 0 mg/kg/d | 1.8 mg/kg/d | 7.1 mg/kg/d | 14.3 mg/kg/d |
| M   | 0 mg/kg/d | 1.8 mg/kg/d | 7.1 mg/kg/d | 14.3 mg/kg/d |
| F   | 0 mg/kg/d | 1.8 mg/kg/d | 7.1 mg/kg/d | 14.3 mg/kg/d |
| Forestomach hyperplasia | M | 4 | 8% | 16%* | 18%* |
| F | 4 | 4% | 10% | 14%* |
| Forestomach papilloma/carcinoma | M | 6 | 8% | 52%* | 64%* |
| F | 6 | 14% | 50%* | 58%* |
| Harderian gland hyperplasia | M | 2 | 8% | 14%* | 8% |
| F | 10 | 8% | 12% | 16% |
| Harderian gland adenoma/carcinoma | M | 12 | 32%* | 54%* | 60%* |
| F | 22 | 20% | 52%* | 50%* |
encephalic glyomas (oligodendrogliomas) in all dosed groups. In addition, a significant increase in incidences of Zymbal’s gland carcinomas was observed in male offspring.

**Study in mice**

In a 2-year carcinogenicity study in B6C3F1 mice administered acrylonitrile by gavage, increases in the incidences of neoplasia in two target organs, forestomach and Harderian gland, were observed in both sexes at 10 and 20 mg/kg body weight per day. In males, the percent incidences of Harderian gland adenoma and carcinoma were significantly increased at all tested dose levels, from 2.5 to 20 mg/kg/day of acrylonitrile, and in females at 10 and 20 mg/kg/day (Tables 6 and 7). Noteworthy, in both sexes, over 90% of all tumors of the Harderian gland were benign adenomas. Increased incidences of combined alveolar/bronchiolar adenomas and carcinomas, as well as benign/malignant granulosa cell tumors of the ovary, were reported only in female mice from a mid-dose group (10 mg/kg/day). These findings were considered equivocal due to a lack of dose-response.

**Summary of carcinogenicity findings with regard to potential MoA**

The difference in the target organs of carcinogenicity between rats and mice denotes inter-rodent variations, supporting the concept that acrylonitrile-induced neoplasia is “species-specific,” with exception of the forestomach which was a common tumor site in both species with oral administration. Overall, responses were similar between the sexes, although, in a few studies, female rats were more

---

### Table 7. Thresholds for neoplasms produced by acrylonitrile in rodent carcinogenicity bioassays.

| Study and experimental design | Forestomach neoplasms | Brain neoplasms | Zymbal’s gland neoplasms | Harderian gland neoplasms |
|------------------------------|-----------------------|----------------|------------------------|--------------------------|
|                              | NOAEL (mg/kg bw/d)    | LOAEL (mg/kg bw/d) | NOAEL (mg/kg bw/d) | LOAEL (mg/kg bw/d) | NOAEL (mg/kg bw/d) | LOAEL (mg/kg bw/d) |
| 1) Quast 2002               | M 3.4                 | 8.5           | –                      | 3.4                     | 8.5                 | 21.3             |
| 0, 35, 100, 300 ppm in drinking water to SD rats (48/sex/dose) | F 4.4 | 10.8 | – | 4.4 | 4.4 | |
| 2) Johannsen and Levinskas 2002a | M 8 | – | 8 | – | 0.09 | 8 |
| 0, 1, 100 ppm in drinking water to SD rats (100/sex/dose) | F 0.15 | 10.7 | 0.15 | 10.7 | 0.15 | 10.7 |
| 3) Johannsen and Levinskas 2002b | M 0.1* | 0.3 | 0.8 | 2.5 | 0.8 | 2.5 |
| 0, 1, 3, 10, 30, 100 ppm in drinking water to F344 rats (100/sex/dose) | F 1.3* | 3.7 | 1.3 | 3.7 | 0.4 | 1.3 |
| 4) Johannsen and Levinskas 2002a | M 0.1 | 10 | 0.1 | 10 | 0.1 | 10 |
| 0, 0.1, 10 mg/kg/d by gavage, 7 days/wk, to SD rats (100/sex/dose) | F 0.1 | 10 | 0.1 | 10 | 0.1 | 10 |
| 5) Quast et al. 1980 | M 9b | – | 2b | 9b | 2b | 9b |
| 0, 20, 80 ppm by inhalation, 6 hrs/d, 5 days/wk to SD rats (100/sex/dose) | F 13.5b | – | – | 2.6b | 2.6b | 13.5b |
| 6) Ghanayem et al. 2002; NTP 2001 | M 1.8c | 7.1c | N/D | N/D | – | 1.8c |
| 0, 2.5, 10, 20 mg/kg/d by gavage, 5 days/wk, to B6C3F1 mice (50/sex/dose) | F 1.8c | 7.1c | N/D | N/D | 1.8c | 7.1c |

F, female; M, male; N/D, not detected; *, threshold not established; LOAEL, lowest-observed-adverse-effect-level; NOAEL, no-observed-adverse-effect-level.

*No significant increase in forestomach neoplasms were observed in the high dose group (100 ppm).
†Equivalent dose; details for calculations are provided in a footnote of Table 2.
‡Represent adjusted 7 days per week intake levels of 2.5, 10, and 20 mg/kg body weight administered 5 days per week.
susceptible to brain or Zymbal’s gland carcinogenicity (Table 7). Target organs of acrylonitrile carcinogenicity are the sites of spontaneous background neoplasms, indicating the susceptibility of these tissues to tumor development.

Rates of “spontaneous” forestomach squamous cell carcinomas or papilloma’s range between 0.08 and 0.25% in F344 and SD rats and between 1 and 2% in B6C3F1 mice. Forestomach squamous cell neoplasia is the sixth most commonly induced neoplasm in NTP rodent carcinogenicity assays and is similar in histological appearance in all rodent species and strains. Two recognized key events involved in the development of forestomach neoplasms are DNA damage and chronic irritation. Moreover, an association between early epithelial cell proliferation and hyperkeratosis and development of forestomach neoplasm was described for several carcinogens, especially following chronic administration by gavage.

The incidence of “spontaneous” brain glial neoplasms in rodents is low, that is, 1–2%, although, with advancing age, rats develop these neoplasms more commonly than mice. In the F344 rat, their incidence is lower than that of the SD strain. While previous studies reported that “astrocytomas” have been the most commonly identified brain tumors by conventional histopathology analyses, based on immunohistochemical analyses, commonly observed background glial brain tumor in rats were primarily oligodendroglialoma. Staining characteristics of other, less common spontaneous tumors previously diagnosed as astrocytomas suggested origin from monocytic cells, and thus they were diagnosed as malignant microglial tumors.

Genotoxicity is an accepted MoA for several compounds. As suggested by ethylene oxide, the existence of thresholds for acrylonitrile tumorigenicity is plausible.

Overall, in rats, the lowest-observed-adverse-effect-level (LOAEL) for neoplasia induction by acrylonitrile in target organs was at least 0.3 mg/kg/day, and the lowest NOAEL was 0.09 mg/kg (Table 7). In mice, the LOAEL was at least 1.8 mg/kg/day, and the NOAEL was below this concentration (Table 7). According to the Carcinogenic Potency Database (CPDB, https://toxnet.nlm.nih.gov/cpdb/chempages/ACRYLONITRILE.html), median tumor doses (TD50) for acrylonitrile are estimated to be 16.9 and 6.32 mg/kg per body weight per day, for rat and mouse, respectively. BMD modeling showed that overall, the potency of acrylonitrile was consistent for different tumor types across studies with different routes of acrylonitrile administration (Figure 1). Male rats and mice in most cases were more susceptible to carcinogenic effects of acrylonitrile, compared to females. Acrylonitrile was more potent in mice compared to rats. Analyzing each tumor type separately, the lowest BMDL for the brain tumor incidence in rats of both sexes was ~2 mg/kg body weight (Figure 1a). BMDs for forestomach tumors could not be computed in F344 rats of both sexes from the drinking water study, and in female SD rats from the inhalation study. The failure to estimate BMDs for these groups could be due to the fact that maximum tumor increase in the dosed groups was smaller than specified benchmark response of 10% (Suppl. Figures 2 and 3). Based on the remaining data, the lowest BMDLs for forestomach tumors were 1.7 mg/kg in rats and ~1 mg/kg in mice (Figure 1b and d). The lowest BMDL for the Zymbal’s gland tumors in rats was 2.7 mg/kg, and 1.2 mg/kg for Harderian gland tumors in mice (Figure 1c and d).

CSF for all tumor types was estimated to range from 0.01 to 0.06 mg/kg per day based on the findings in the rat studies, and from 0.06 to 0.09 mg/kg per day based on the study conducted in mice. An oral multi-tumor Slope Factor of 0.03 per mg/kg per day was derived from a geometric mean for all rat studies with acrylonitrile administration in drinking water. In order to estimate human risk from inhalation exposure, inhalation cancer unit risk factors (CSF expressed as μg/m3) were also calculated.
based on the tumor incidences in the inhalation study in rats (Quast et al. 1980) using the concentration in μg/m³ ($43.4 \times 10^{-3}$ and $173.6 \times 10^{-3}$ μg/m³). The geometric mean for all tumors in both sexes of rats was estimated to be $1.02 \times 10^{-6}$. Individual values for each tumor type and sex are provided in Supplemental Table 1.

US EPA (2006) estimated an inhalation unit risk for acrylonitrile of $6.8 \times 10^{-3}$ per μg/m³, and that inhalation of 1 μg/m³ acrylonitrile in the air over the lifetime of an individual would result in not greater than one-in-ten thousand increased risk of developing cancer. This estimate is adjusted for smoking and continuous lifetime equivalent of occupational exposure, and thus, is different from the calculations above.

Previous cancer dose-response modeling of acrylonitrile cancer potency, based on the findings in rodent carcinogenicity, PBPK prediction for internal peak dose of CEO in the brain, and mechanistic studies, established that oral doses below 0.009 mg/kg/day and air concentrations below 0.1 mg/m³ are not expected to pose an exposure risk to humans.

Review of key characteristics of acrylonitrile relevant to its mechanism of action

Electrophilicity and metabolic activation

Chemical characteristics and reactivity data. Acrylonitrile (CAS: 107-13-1) is a 3-carbon alkene, with a nitrile substituent group (Figure 2). It is a direct alkylating compound,
which is highly reactive due to the presence of an olefinic group (double bond between two carbons) and nitrile group (cyano radical). The olefinic group can react with many substances, such as ammonia, halogens, alcohols, and can undergo polymerization, oxidation, and hydrogenation. The nitrile group can also undergo transformation including hydrolysis, esterification, and reduction. In addition, the cyano radical can react with various nucleophiles in cyanoethylation reactions. Thus, acrylonitrile and its metabolite, CEO, have the structure of an electrophile.

**Chemico-kinetic characteristics.** Acrylonitrile is rapidly absorbed after either enteral or parenteral administration and distributed to all tissues in rats and mice. It is mainly metabolized in the liver by two major pathways; one involves a direct conjugation with reduced glutathione, while the other entails oxidation by cytochrome P-450 to an epoxide intermediate, CEO (Figure 2). Acrylonitrile and CEO are chemically reactive, although both are relatively stable, with acrylonitrile having a half-life of 8 hrs, and CEO of approximately 1.5 hrs.

In vivo, conjugation of acrylonitrile with GSH is rapid. This reaction results in the formation of major acrylonitrile products, mercapturic acids (N-acetyl-S-(2-cyanoethyl)-L-cysteine and N-acetyl-S-(1-cyano-2-hydroxyethyl)-L-cysteine) (Figure 2). The pattern of excretion of these metabolites is proportional to the administered dose and route of administration, suggesting the existence of a saturable pathway which competes with GSH for acrylonitrile. Species differences in the metabolism of the GSH conjugates have been noted but are not considered to be of toxicological significance. Thus, in vitro, acrylonitrile reaction with GSH follows hyperbolic kinetics, and mouse enzymes have four to sixfold higher affinity for GSH conjugation of acrylonitrile compared to rat cytosol. Decrease of liver GSH by 43% results in a 50% increase in acrylonitrile-derived undialyzable radiolabel in blood, brain, lung, stomach, and kidney. The authors also observed a
300% increase in urinary metabolite derived from the epoxide pathway in glutathione depleted rats. In the livers of SD rats, acrylonitrile is selective for glutathione s-transferase (GST) subunit, GSTM1. In humans, acrylonitrile is metabolized by GSTP1 and not GSTM1 and functional polymorphism in GST isoforms, GSTP1 and GSTT1, can potentially underlie interindividual susceptibility to acrylonitrile toxicity.

An alternative route of acrylonitrile metabolism, epoxidation to CEO, is mediated primarily by CYP2E1 in rodents and humans (Figure 2). This reaction occurs mostly in the liver, although lung tissue may also contribute to the metabolism of inhaled acrylonitrile. Mice biotransform acrylonitrile in greater proportion via the CYP2E1-mediated oxidative pathway compared to rats. Thus, the rate of CEO formation in liver microsome preparations is 501 pmol/min-mg protein in humans compared to 667 in rats, and 2801 in mouse. However, CEO concentrations in blood and brain of rats are higher (about 428 pmol/ml in blood and 433 pmol/g in brain) than in mice (about 380 pmol/ml in blood and 351 pmol/g in brain).

CEO can be further oxidized to cyanide (Figure 2), mostly via epoxide hydrolase or a cytochrome P-450-dependent mixed-function oxidase system in hepatic microsomes. In contrast to humans, in rat and mouse liver cytosol or microsomes, epoxide hydrolase is inactive to CEO substrate. In rats and mice, inhibition of CYP2E1 enzyme prevents an increase in levels of cyanide and

**Figure 3.** Proposed mechanisms of action (MoA) of acrylonitrile associated neoplasia. Solid arrows indicate direct key event relationships; broken arrows indicate indirect key event relationships. CEO, 2-cyanoethylenoxide.
significantly decreases the toxicity of acrylonitrile.\(^{77–79}\) Higher levels of oxidative metabolism of CEO in humans compared to rodents could result in different manifestations of acrylonitrile toxicity, and CYP2E1 polymorphism in humans might correlate with interindividual susceptibility to cyanide toxicity.\(^{51,80}\) Lactoperoxidase found in lacrimal, salivary, mammary glands, and airways was also demonstrated to oxidize acrylonitrile to cyanide in vitro.\(^{81}\)

CEO is also detoxified by conjugation mediated by GST with consequent formation of mercapturic acids (Figure 2). In addition, reaction of CEO with GSH can lead to production of cyanide.\(^{82}\)

Rats and mice exhibit dose-dependent increase in cyanide levels following administration of acrylonitrile, with highest levels recorded in blood and liver, followed by kidney and brain.\(^{83}\) Higher levels of cyanide were observed in the tissues of rats compared to those in mice after oral administration of acrylonitrile at a dose equivalent to the LD\(_{50}\) (46.5 mg/kg for rats and 13.5 mg/kg for mice). After 1 h of administration, respective cyanide concentrations in blood, liver, and brain were 120 nmol/ml, 110 nmol/g, and 38 nmol/g in rats compared to 92 nmol/ml, 85, and 19 nmol/g in mice. However, mice metabolized acrylonitrile to cyanide faster compared to rats. Thus, a time-course study conducted in male rats and mice administered an equivalent of 50% of the oral LD\(_{50}\) dose (46.5 mg/kg for rats and 13.5 mg/kg for mice) demonstrated that in rats, maximum concentration of cyanide in blood (~110 nmol/ml) is achieved 3 hrs after administration, while in mice blood cyanide concentration is the highest (~57 nmol/ml) at 1 h.\(^{83}\)

High uptake of radioactivity after oral and intravenous administration of [1-\(^{14}\)C]-acrylonitrile was observed in various tissues, including blood, liver, kidney, lung, adrenal cortex, and stomach mucosa.\(^{84}\) However, irreversible binding of radioactivity to proteins, detected after intraperitoneal administration of [2,3-\(^{14}\)C]-acrylonitrile to rats,\(^{85}\) makes it difficult to determine whether these findings are indicative of accumulation of free acrylonitrile, its metabolites or cyanoethylated proteins.

[1-\(^{14}\)C]-acrylonitrile administered to rats by the oral, inhalation, or intravenous routes produces recoverable radioactivity mainly in the urine (about 65% after oral or inhalation) followed by carcass (about 10% after oral or inhalation), feces (about 3% after oral or inhalation), and \(^{14}\)CO\(_2\) (about 3% after oral, or inhalation).\(^{86,87}\) At least 95% of acrylonitrile is absorbed within the first 72 hrs.\(^{87}\) In mice, similar data were obtained.\(^{88}\) In general, radioactivity is detected in several tissues, regardless of the route of administration, dose level, or duration of exposure. The stomach, red blood cells, and skin showed the greatest levels of acrylonitrile distribution, followed by lungs, liver, kidneys, intestines, skeletal muscle, heart, spleen, brain, thymus, and testes.\(^{61,75,87,89}\)

At 48 hrs after oral dosing, 61% of a dose of radioactive acrylonitrile is excreted by rats, with 53% in feces, 4% in urine, and 4% as exhaled CO\(_2\). With intravenous administration, elimination over 48 hrs is 21% in feces, 8% in urine, and 2% in expired air.\(^{89}\) Kedderis et al.\(^{88}\) estimated that 3–5% of acrylonitrile doses (0.09–28.8 mg/kg orally) are excreted in feces of rats, while 2–8% of the dose (0.09–10 mg/kg orally) is recovered from the feces of mice. Similarly, 72 hrs following the same oral doses as above, 73–99% of the radioactive dose was excreted in the urine, while 3–5% was found in feces. In mice, receiving orally the same range of doses as above, 83–94% of the dose is excreted in the urine and 2–8% in feces. Excretion is not dose-dependent in either species. Analysis of urine metabolites after oral administration of [2,3-\(^{14}\)C]-CEO in rodents revealed that approximately 55% of the CEO metabolites are excreted in the urine in rats and 75% in mice.\(^{88}\) In humans, acrylonitrile and its metabolites thiocyanate and mercapturic acid are mainly eliminated in urine.\(^{1}\)

Thus, chemical kinetic data reveals high bioavailability of acrylonitrile, with widespread distribution throughout the body. It is likely that the reactive metabolite CEO and the toxic metabolite cyanide form predominantly in the liver (which, however, is not a target organ for carcinogenicity), but may also have widespread distribution throughout the body in the circulation, with potential exposure of target organs. Nevertheless, CEO is cleared faster by the mouse liver, and consequently, the rat has higher blood and brain CEO levels compared to respective mouse levels. Overall, the elimination of acrylonitrile is mostly complete, without any accumulation. Lack of accumulation is supported by a study showing that 28-day dosing of rats did not affect the binding of subsequently administered radiolabeled acrylonitrile in brain.\(^{24}\)

Review of animal toxicity data

Acute toxicity. Acrylonitrile produced acute toxicity in experimental animals regardless of the route of administration.\(^{3}\) The toxicity of acrylonitrile could result either from direct effects or from effects of its metabolites, CEO or cyanide (Figure 2). Oral median lethal dose (LD\(_{50}\)) values for acrylonitrile range from 25 to 186 mg/kg body weight, with the mouse being the most sensitive species and rat the least (Table 8). Acute inhalation toxicity studies yielded LC\(_{50}\) values of 0.3–1.21 mg/L for 4-hour exposure in various species and another study determined a 4-hour LC\(_{50}\) of 2.05 mg/L in rats.\(^{1,3}\) In acute dermal toxicity studies, the rat was the most sensitive species with LD\(_{50}\) values ranging from 148 to 282 mg/kg body weight, followed by the rabbit, 226 mg/kg, and the guinea pig, 260–690 mg/kg. Studies with other routes of administration (subcutaneous, intravenous, and intraperitoneal)
yielded LD50 values similar to those from oral toxicity studies (Table 8).

Signs of neurotoxicity were commonly observed in the majority of acute toxicity studies. They occurred in stages, starting with agitation and lacrimation in the excitatory phase, salivation, lacrimation, urination, and defecation during a tranquil phase, which was followed by seizures (convulsive phase), paralysis (paralytic phase), and death. Edema of the brain and lungs, as well as bleeding in the gastrointestinal tract and hemorrhagic necrosis of the adrenals, were also observed. A single dose of acrylonitrile at 20, 40, or 80 mg/kg body weight administered to male Sprague-Dawley (SD) rats by gavage or subcutaneous injection also produced neurotoxic effects, cholinomimetic in nature. The signs included salivation, lacrimation, miosis, vasodilation, and diarrhea. Pre-dosing with atropine protected rats from the neurotoxicity, suggesting possible involvement of the cholinergic system in acute toxicity produced by acrylonitrile.

A single oral administration of acrylonitrile by gavage at LD50 levels to male SD rats (93 mg/kg) and male Albino-Swiss mice (27 mg/kg) resulted in different symptoms of toxicity in both species. Specifically, while rats developed cholinomimetic signs of toxicity (salivation, lacrimation, diarrhea, wheezing, peripheral vasodilation), mice developed CNS disturbances, such as depression, agitation, convulsions, and asphyxia.

The acute toxicity of acrylonitrile has been proposed to result from its bioactivation by cytochrome P450 enzymes leading to formation of cyanide (Figure 2). In wild-type mice (mixed 129/Sv and C57BL strains) of both sexes dosed at up to 40 mg/kg of acrylonitrile by gavage in a single dose, increase in lethality was associated with dose-dependent increase of cyanide levels in blood (in males up to 120 nmol/ml and in females up to 40 nmol/ml one hour after exposure) and brain (in males up to 60 nmol/ml and in females up to 10 nmol/ml one hour after exposure). In contrast, CYP2E1-deficient mice did not exhibit significant signs of toxicity, and cyanide levels in their blood and brain tissue were comparable to that of the control group. Ahmed and Patel suggested a role for cyanide formation in acrylonitrile-produced toxicity in rodents which is species dependent. In mice, which metabolize acrylonitrile faster, cyanide formation is the major mechanism of toxicity, whereas in rats, it plays a minor role.

Others suggest that binding of acrylonitrile to cysteine residues on proteins can lead to inhibition of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Thus, in vitro acrylonitrile at 200 μM for 1 h irreversibly inhibited GAPDH activity by 90% due to alkylation of Cys149 residue of the enzyme. These events might contribute to inhibition of oxidative phosphorylation in mitochondria as well as impaired glycolytic ATP production. While mitochondrial damage was described in vitro after long-term acrylonitrile administration, no ATP depletion was observed in the brain tissues of male SD rats exposed to a single subcutaneous injection of a LD90 dose (115 mg/kg) of acrylonitrile, suggesting that other mechanisms also may be involved in the acute toxicity of this compound.

Depletion of GSH is likely to exacerbate toxicity of acrylonitrile. Thus, a single subcutaneous dose of acrylonitrile administered to male SD rats at 30 or 50 mg/kg body weight produced focal erosions of glandular stomach mucosa, which became more severe with time and were associated with hepatic and gastric glutathione depletion.

### Table 8. Acute toxicity of acrylonitrile in different species.

| Route of administration | Reported LD50 and LC50 values | Mouse | Rat | Guinea pig | Rabbit | Effects |
|-------------------------|-------------------------------|-------|-----|------------|--------|---------|
| Oral                    | 25–48 mg/kg<sup>a</sup>       | 72–186 mg/kg<sup>a</sup> | 50–85 mg/kg<sup>a</sup> | 93 mg/kg<sup>b</sup> | Seizures, paralyses, dyspnea, agitation, salivation, lacrimation |
| Inhalation (4 h)        | 0.3 mg/L<sup>a</sup>          | 425 ppm<sup>c</sup> | 576 ppm<sup>a</sup> | 260 ppm<sup>d</sup> | Dyspnea, tremor, lacrimation |
| Skin                    | 148–282 mg/kg<sup>a</sup>     | 1.21–2.05 mg/L<sup>a</sup> | 0.99 mg/L<sup>a</sup> | 226 mg/kg<sup>e</sup> | Dermatitis, somnolence |
| Subcutaneous            | 25–50 mg/kg<sup>a</sup>       | 80–96 mg/kg<sup>a</sup> | 130 mg/kg<sup>a</sup> | 63 mg/kg<sup>e</sup> | Tremor, convulsions, flaccid paralysis with anesthesia |
| Intravenous             | 47–50 mg/kg<sup>a</sup>       | 65–100 mg/kg<sup>a</sup> | 72 mg/kg<sup>a</sup> | 69 mg/kg<sup>a</sup> | Convulsions, tremor, flaccid paralysis with anesthesia |
| Intraperitoneal         |                               |       |     |            |        | Dyspnea, ataxia, corneal damage |

LD50, median lethal dose.
<sup>a</sup>ECHA 2018.<sup>3</sup>
<sup>b</sup>Snyder 1990.<sup>90</sup>
<sup>c</sup>Lewis 2004.<sup>91</sup>
<sup>d</sup>ChemIDplus database https://chem.nlm.nih.gov/chemidplus/name/acrylonitrile.
(25% decrease in liver and 50% decrease in glandular stomach). In this study, rats which were pretreated with sulphydryl-containing compounds, as well as atropine, were protected against necrosis and gastric erosions, suggesting that acrylonitrile alters cholinergic receptors by depleting endogenous sulphydryl groups. A similar effect on GSH depletion was observed in male SD rats administered a single oral dose of 23 mg/kg of acrylonitrile, which decreased gastric glutathione levels by 50%, 4 hrs after administration, and 46 mg/kg of acrylonitrile further decreased the glutathione level to 27% of the control group.

Szabo and colleagues reported that intravenous administration of a single dose of acrylonitrile at 150 mg/kg to female SD rats resulted in rapid depletion (80–90%) of glutathione in the liver, lung, and kidney in the absence of cell damage in these organs, while in a target tissue for acrylonitrile carcinogenicity, brain, GSH depletion was more gradual (approximately 30% depletion at the highest dose) but correlated with mortality. GSH levels in the liver at lower dose levels of 10 and 50 mg/kg were decreased by approximately 25% and 60%, respectively. Similar findings were obtained in the rat study with a single subcutaneous dose of acrylonitrile. Thus, 20 mg/kg of acrylonitrile, a dose which did not produce toxicity in acute toxicity studies, produced a 50% decrease in GSH levels in the liver of male SD rats, while the LD_{50} dose of 50 mg/kg depleted GSH by up to 85%. The two highest doses, 80 mg/kg (equivalent of the LD_{50} dose) and 115 mg/kg (equivalent of the LD_{90} dose) almost entirely depleted liver GSH within 30 and 15 min, respectively.

While the brain was more resistant to GSH depletion, a dose-dependent decrease was demonstrated at doses that exhibit toxicity (50, 80, and 115 mg/kg), with 10% depletion at the highest dose. Importantly, GSH levels showed little recovery in the brain, unlike in non-target tissues, liver, and kidney. GSH depletion in the forestomach (another target organ for acrylonitrile carcinogenicity) and glandular stomach was about 40% at the highest dose and occurred at a slower rate compared to other tissues; similar to the brain, no GSH recovery was observed in these tissues. The GSH depletion was accompanied by a dose-dependent increase in cyanide levels, at the highest dose reaching approximately 160 nmol/ml in the blood and over 20 nmol/g in the brain. Toxic levels of cyanide persisted in the blood and brain for 2 hours after exposure to 50 and 80 mg/kg of acrylonitrile and remained at the same level after 4 hrs from exposure to 115 mg/kg of acrylonitrile. Thus, the authors concluded that an increase in cyanide levels result from the inability of the liver to detoxify acrylonitrile due to depletion of GSH (Figure 2).

Based on the outcomes of dermal and ocular irritation studies, in which acrylonitrile administration to rabbits at 0.5 mL (skin) or 0.1 mL (eye) produced erythema, edema, corneal opacity, and severe conjunctival irritation, acrylonitrile is classified as a skin and eye irritant. In addition, the guinea pig maximization test provided clear evidence of skin sensitization following acrylonitrile exposure at 0.2, 0.5 and 1%.

Subacute and subchronic repeat-dose toxicity. Repeat-dose subacute or subchronic administration of acrylonitrile in drinking water or by gavage to rats or mice often produced changes in the forestomach and adrenal gland, as well as signs of general intoxication and neurotoxicity, while inhalation exposure produced changes in the nasal mucosa of rats. Findings in repeat-dose drinking water or gavage studies in rodents were consistent with findings in studies with single-dose administration of acrylonitrile.

In female SD rats administered acrylonitrile at 0.05% and 0.2% in drinking water or by gavage for 7, 21, or 60 days, acrylonitrile toxicity was observed in the gastrointestinal tract. This effect was absent at lower doses of 0.001% (1 ppm), 0.002%, and 0.01%. Specifically, hemorrhagic necrosis and cell proliferation (hyperplasia) of mucosa at the junction between the forestomach and glandular stomach was recorded in rats that received 0.05% and 0.2% of acrylonitrile for 21 and 60 days. These concentrations also caused decreases in food and water intake, the latter possibly representing an effect of poor palatability. These effects led to decreases in body weight gain. In this study, atrophy of adrenal gland, in particular zona fasciculata, was observed in rats that received 0.05% and 0.2% acrylonitrile for 7 and 21 days, in contrast, after 60 days of dosing adrenal hyperplasia occurred and was especially prominent in groups that received acrylonitrile by gavage. Concurrent dose- and time-dependent decreases in circulating cortisone levels were also reported.

Dose-dependent increase in hyperplasia of forestomach mucosa, which was accompanied by an increase in apoptosis, was also reported in male Fischer 344 (F344) rats after daily administration of acrylonitrile by gavage at 0.22 or 0.43 mmol/kg for 6 weeks. Male SD rats that were administered acrylonitrile either by oral gavage at 12.5, 25, and 50 mg/kg for 5 days per week for 12 weeks or through inhalation exposure to 25, 50, and 100 ppm of acrylonitrile for 6 hrs daily, 5 days per week for 24 weeks, exhibited signs of neurotoxicity, which were similar to the findings in the single-dose study by Ghayem et al. These signs, including salivation, lacrimation, miosis, and diarrhea, resembled acute acetylcholine toxicity. These effects became more pronounced with time, suggesting sensitization to acrylonitrile. In addition, a decrease in body weight gain was observed in groups dosed with 25 and 50 mg/kg of acrylonitrile in the oral study and in the high dose group (100 ppm) in the inhalation study.

A few general toxic effects were reported in a 90-day study in SD rats administered acrylonitrile in drinking water at 35, 85, 210, and 500 ppm. These included decreased
water consumption accompanied by decreased body weight gain and an increase in relative liver weight at 210 and 500 ppm groups, in rats of both sexes. A no-adverse-effect level (NOAEL) of 85 ppm (8–10 mg/kg body weight) was established in this study.

Daily administration of up to 60 mg/kg body weight of acrylonitrile to B6C3F1 mice by gavage 5 days per week for 14 weeks resulted in high mortality in both sexes. At 40 mg/kg/day, survival and mean body weight gain of female mice were significantly higher compared to that of males, suggesting that male mice are more sensitive to acrylonitrile toxicity than females. In female mice, acrylonitrile at 40 mg/kg/day produced mild chronic inflammation and hyperplastic changes in the forestomach, as well as mild hematologic effects (lymphocytopenia and hemolytic anemia), which, with exception of hemolytic anemia, also occurred in males administered 20 mg/kg/day. Hematologic findings were suggested to be a result of cyanide formation or binding of acrylonitrile to hemoglobin. The dosage of 5 mg/kg/day was considered to be a NOAEL. Another 13-week study with acrylonitrile administered to B6C3F1 mice by gavage 5 days per week yielded a NOAEL of 12 mg/kg/day (the highest tested dose in the study), since no dose-related effects were observed.

A decrease in body weight gain, signs of neurotoxicity (hypertrophy, behavior, excessive salivation), as well as thickening of the non-glandular stomach (forestomach) were observed in pregnant SD rats, which received acrylonitrile at 65 mg/kg body weight per day by oral gavage from day 6 to day 15 of gestation. In contrast, no forestomach thickening was reported in pregnant rats after inhalation with up to 80 ppm of acrylonitrile for the same duration (equivalent to 23 mg/kg body weight per day of acrylonitrile by gavage).

In studies with acrylonitrile administered to SD rats by inhalation at concentrations of 5, 15, and 45 ppm (two-generation study) and 90 ppm (one-generation study) 6 hrs/day, 5 days/week, signs of systemic toxicity were observed in adult rats in two generations at 45 and 90 ppm in both sexes. The NOAEL for parental systemic toxicity was established as 15 ppm. In addition, acrylonitrile-related microscopic nasal lesions predominantly in rostral epithelium, including respiratory/transitional epithelial hyperplasia, subacute inflammation, squamous metaplasia, and/or degeneration of the olfactory epithelium, were observed in some animals at 5 and 45 ppm of acrylonitrile.

In a three-generation study with acrylonitrile administered in drinking water, the parental generation of SD rats of both sexes that received 100 and 500 ppm of acrylonitrile (corresponding to approximately 11 and 37 mg/kg, respectively, for males and 20 and 40 mg/kg per day for the females, respectively) exhibited decreased water intake and, at 500 ppm, food intake, as well as a decrease in body weight gain compared to the control groups. The F1 offspring mortality was increased at 500 ppm. No signs of neurotoxicity were observed in the study. Increases in the incidences of astrocytoma and Zymbal’s gland tumors were observed in adult females in each generation after almost a year of dosing. Tumor rates in F2 generation were lower compared to F1 and comparable to F0, suggesting minimal in utero effect.

**Genotoxicity and binding to macromolecules.** DNA-reactivity and mutagenicity in the target tissues represent a key MoA for a certain type of chemical carcinogen referred to as DNA-reactive or genotoxic. Thus, a important question in assessing the MoA of acrylonitrile is whether its electrophilic structure can lead to covalent binding to DNA, resulting in genotoxicity (Table 1).

**Binding to macromolecules.** Some data suggest that acrylonitrile can form DNA adducts in several organs (e.g., brain, liver), but evidence of covalent binding to DNA is uncertain. Alkylation of DNA was mainly due to DNA binding of the reactive metabolite CEO which is faster compared to acrylonitrile.

Irreversible binding of 2,3-14C-2-acrylonitrile and CEO to calf thymus DNA and microsomal protein was demonstrated in vitro. Dose-related covalent binding of CEO to DNA with formation of N7-(2-oxoethyl) guanine (N7-OEG) adducts was also observed in human TK6 lymphoblastoid cells following 2-hour incubation with 35 or 105 μM [2,3-14C]-CEO and in DNA extracted from brains and livers of control F344 rats and incubated with 1.07, 5.33, and 53.5 μM of CEO for 8 hours. Several other studies reported acrylonitrile binding to DNA in vivo, with N7-OEG being the major acrylonitrile-specific adduct, in addition, N6-ethenodeoxyadenosine and 3,N4-etheno-deoxycytidine are among the most commonly observed adducts. However, the sensitivity of these studies was limited, since they used low specific activity 14C-acrylonitrile in conjunction with liquid scintillation counting. Low levels of “binding” to DNA were largely attributed to binding to contaminating protein, since following DNA digestion residual radioactivity was not associated with nucleotides.

In vivo detection of acrylonitrile-specific promutagenic etheno-adducts has been largely unsuccessful. DNA alkylation by acrylonitrile in F344 rat brain was calculated to be below 1 adduct per 108 normal nucleotides. No etheno-DNA adducts were detected in target tissues (brain and forestomach) or non-target tissues (liver and spleen) after administration of acrylonitrile in drinking water to male F344 rats at 3,10, 35, 100, or 300 ppm (doses equivalent to those used in 2-year carcinogenicity bioassay) for 105 days and to both sexes at 500 ppm for 15 months. N7-OEG adducts were absent in target tissues, brain or forestomach, or non-target tissue spleen, and were observed...
only in non-target tissue, liver, at 300 and 500 ppm; however, the levels of binding were close to the detection limit.

In studies by Farooqui and Ahmed,17,112 DNA adduct levels were almost 10 times higher in the brain (56 in 10^6 normal nucleotides) than in the liver. DNA adduct levels were relatively stable increasing over the first 24 hrs and remained approximately the same at 48 hrs, the last time point studied. The authors commented that the radioactivity was found in peaks “corresponding to standard DNA nucleosides deoxyadenosine and deoxyguanosine,” which would be consistent with metabolic incorporation of 14C rather than DNA binding. High levels of DNA adducts in the brain of male F344 rats were also detected after single administration of 4 mg/kg of [2,3-14C] acrylonitrile either orally or by inhalation to rats with depleted glutathione.66,119 However, when samples were digested with RNase, the residual radioactivity was at or below the detection limit of about 3 adducts per 10^6 normal nucleotides.

The conflicting evidence for DNA adduct formation in the brain was reviewed by Whysner et al.116,120 with the conclusion that reported “DNA adducts” were most likely a result of contamination by acrylonitrile bound to residual protein.

Abdel-Rahman and coauthors121 reported very rapid DNA binding of 2,3,14C-acrylonitrile in gastric glandular tissues after a single oral dose, with adduct levels in the order of 1 adduct in 10^3 nucleotides, which, however, declined after 15 min. Such high levels of adducts are unusual for any chemical. The authors stated that DNA was free from protein based on 260/280 ratios, which, however, is very insensitive for protein contamination of nucleic acids. If this radioactivity represented DNA adducts, the vast majority are rapidly repaired. Similar results were obtained by the authors in the lungs122 and testes,123 which were not target tissues of neoplasia in rodents. In these studies, no attempt was made to investigate metabolic incorporation of 14C into the normal DNA nucleotides. Radioactivity from 2,3,14C-acrylonitrile was incorporated into normal RNA bases in the liver of Wistar rats with higher incorporation at 72 hrs compared to 24 hrs. In contrast, little or no radioactivity was incorporated into DNA nucleotides and the amount of adducts was too low to allow for identification, however, the authors presumed that acrylonitrile, either itself or its metabolites, can alkylate nucleic acids.124,125 Regardless, such DNA-binding was much lower when compared to vinyl halides.

Williams et al.24 assessed acrylonitrile-DNA adduct formation in SD and F344 rat brain tissues after a single oral gavage dose of 11 mg/kg body weight 14C-acrylonitrile, which in some groups was preceded by administration of acrylonitrile in drinking water at 100 ppm for 27 days. Binding of 2,3-14C-acrylonitrile to purified DNA was measured using accelerator mass spectrometry, which is orders of magnitude more sensitive than liquid scintillation counting.126 Association of 14C-acrylonitrile with DNA in the brain was detected, but possible binding represented less than 15 adducts per 10^8 nucleotides, which is considered to be of questionable biological significance.58 Moreover, despite extensive purification, protein contamination of DNA was considered still possible.24 The absence of DNA adducts in acrylonitrile-dosed groups was confirmed with 32P-nucleotide post labeling, which can detect one adduct in 10^10 nucleotides.127

Evidence exists that binding of acrylonitrile to protein is much higher than to nucleic acids and that thiols are a major target, with GSH playing a strong protective role.128 The reaction does not appear to be enhanced by metabolic activation.129 Both acrylonitrile and CEO react rapidly with GSH under physiological conditions (e.g., the temperature of 37°C) due to high reactivity of thiol groups.63,64 However, CEO reacts with GSH less rapidly compared to acrylonitrile. Thus, in vitro studies using hepatocytes isolated from F344 rats demonstrated that most of the binding to GSH and protein was a result of direct reaction of acrylonitrile, rather than metabolic activation to CEO.130 Rapid depletion of GSH, up to 85% compared to control, was recorded in rat hepatocytes 10 min after administration of 5 and 10 mM of acrylonitrile, while at 0.1 mM acrylonitrile had minimal effect on GSH levels. These effects corresponded with the dose-dependent increase in cytotoxicity of acrylonitrile. With depletion of GSH, the binding of CEO to macromolecules increases disproportionately.101,128 Thus, covalent binding of acrylonitrile at doses above 1 mmol/kg (equivalent to 50 mg/kg) increased twofold, while 85% depletion of liver GSH was observed.

A protein site identified as particularly reactive was the cysteine 86 moiety of rat GST.67 The levels of protein binding in the brain, kidney, liver, and stomach of male SD rats were about 1 adduct per 10^5 amino acids after a single oral administration of 2,3-14C-acrylonitrile.117,118 Similar levels were found in RNA from the brain, liver, and stomach. Hemoglobin N-terminal valine adducts of acrylonitrile, while constituting only a small percentage of total hemoglobin binding, have been proposed as a marker of both active131 and passive132 smoking or accidental exposure to acrylonitrile.133 Benz et al.124 reported that in rats after subcutaneous administration of 2,3-14C-acrylonitrile, N-(2-cyanoethyl)valine adduct formation, which represented only 0.2% of total acrylonitrile globin adducts, had a linear function at dose levels between 0.02 to 0.95 mmol/kg. In contrast, at higher doses (above 1 mmol/kg), which are known to produce toxicity, a sharp decrease in hemoglobin binding was reported. Similarly, a dose-related increase in N-(2-cyanoethyl)valine hemoglobin adducts was reported in male F344 rats exposed to several concentrations of acrylonitrile in drinking water ranging from 3 to 300 ppm for
105 days. At dosages above 10 ppm, levels of adducts increased sublinearly, indicating saturation of metabolic pathway and elimination of acrylonitrile. In addition, these globin adducts were also detected in smokers consuming 10 to 20 cigarettes per day, whereas in non-smokers they were below detection limit.

In vitro genotoxicity. Acrylonitrile induced mutations, chromosomal damage (chromosome aberrations and sister chromatid exchange), cell transformation, and elicited gene conversion in the yeast assays for chromosomal segregation effects, and cultured mammalian cell assays, while results in bacterial gene mutation (Ames) assay were inconsistent and did not reveal a clear effect (Table 9). Despite positive findings indicative of chromosomal damage, negative results were obtained in DNA repair assay in rat hepatocytes and human mammary epithelial cells.

In the majority of the assays, positive responses were observed only at very high dose levels (3 or 4 times higher than the LOAELs) of acrylonitrile which were associated with cytotoxic effects, indicating its weak mutagenic potential. The induction or enhancement of genotoxicity after metabolic activation, suggests that conversion to CEO may be responsible for the in vitro mutagenicity of acrylonitrile.

In addition, it is possible that oxidative stress could contribute to positive results in some of the assays. Thus, L5178Y cells utilized by the mouse lymphoma assay are known to be sensitive to oxidative damage due to decreased antioxidant defenses.

In vivo genotoxicity. In contrast to in vitro findings, many in vivo studies did not report mutagenicity or clastogenicity of acrylonitrile (Table 10). These include investigations of chromosomal aberrations and formation of micronuclei in somatic cells and studies of heritable chromosome level changes, such as dominant lethality test, in rats and mice after acrylonitrile administration by various routes, including inhalation, oral administration, and intraperitoneal injections. Results in Drosophila mutation assay, unscheduled DNA synthesis, and sister chromatid exchange yielded conflicting results; thus, the significance of these endpoints is unclear (Table 10).

The lack of in vivo genotoxicity can be explained by differences in metabolic activation of acrylonitrile and detoxication/elimination capacities of live animals compared to in vitro systems. As a result, in vivo epoxidation may yield lower levels of CEO, which might be insufficient for the production of DNA damage. In support of this hypothesis, one of the studies reported that induction of unscheduled DNA repair synthesis in the gastric mucosa by acrylonitrile administered to male SD rats as a single oral dose up to 46 mg/kg was associated with dose- and time-dependent GSH depletion (27% of control group). Furthermore, sulfhydryl compounds, cysteine, and penicillamine, protected gastric mucosa from DNA damage.

Mutagenic effects evident by dose-related elevations in Hprt mutated colonies of splenic T-lymphocytes were reported by Walker et al. in female B6C3F1 mice, male lacZ transgenic mice, and F344 rats. Similar effects were also observed in CYP2E1-null mice; however, the dose of acrylonitrile that produced an effect (60 mg/kg/bw) was lethal to wild-type mice. Based on the comparison of the mutagenic effects with analogous compounds, the mutagenic potential was considered as limited, and similar to another epoxide-forming chemical, butadiene. Weak mutagenic effects could stem from either direct or indirect DNA damage. Based on the mainly negative results in in vivo studies of acrylonitrile DNA binding in target tissues, direct genotoxicity is unlikely. The mutagenicity might be a result of CEO reactivity or oxidative damage.

No direct production of DNA strand breaks was detected in the target tissues, brain, and Zymbal’s gland, of SD and F344 rats and Harderian gland of wild-type B6C3F1 or CYP2E1-null mice using a conventional comet assay. Positive comet assay results were reported in forestomach and liver in wild-type B6C3F1 but not CYP2E1-null mice, after administration of acrylonitrile at 20 mg/kg by gavage 5 days/week for 6 weeks, indicating the significance of the oxidative pathway in producing DNA damage by acrylonitrile. The authors noted that the nature of DNA damage detected by comet assay was difficult to determine, since the assay does not differentiate between single-strand breaks and excision-repair and alkali-labile sites (including those formed by repair of N-7-guanine DNA adducts).

Toxicity of acrylonitrile can also affect the outcomes of genotoxicity testing. Thus, while acrylonitrile produced DNA-strand breaks in the livers of male SD rats, no increase in DNA damage was detected in the glandular stomach (non-target tissue), where mild histopathological changes were found compared to remarkable necrosis of squamous cells and ulceration that were observed in forestomach (target tissue) at 62.5 mg/kg administered orally as 3 doses.

Non-genotoxic mechanisms: induction of oxidative stress and inflammation. Oxidative stress has been implicated as a key mechanism of action of carcinogens. However, only a few reports focus on the effect of oxidative damage specifically on microglial cell, which recently were identified as cells of origin for acrylonitrile-induced tumors. In contrast to astrocytes, microglia, which is a counterpart to macrophages, can proliferate, migrate, and change functional status depending upon the location in the CNS. Thus, response of microglia to oxidative stress or other effects of acrylonitrile, CEO, and cyanide should be investigated further.

Increased levels of reactive oxygen species and 8-deoxyoxoguanine adducts in rat glial DITNC1 cell line
Table 9. Summary of findings for acrylonitrile in short term *in vitro* genotoxicity assays.

| Assay                              | Results | Dose                |
|------------------------------------|---------|---------------------|
| **Bacterial gene mutation assay:** |         |                     |
| *Salmonella typhimurium* TA97, reverse mutation | -       | 2500 µg/ml          |
| *Salmonella typhimurium* TA98, reverse mutation | -       | 3333 µg/ml          |
| *Salmonella typhimurium* TA100, reverse mutation | -       | 500 µg/ml           |
| *Salmonella typhimurium* TA100, reverse mutation | -       | 2500 µg/ml          |
| *Salmonella typhimurium* TA102, reverse mutation | -       | 2500 µg/ml          |
| *Salmonella typhimurium* TA1530, reverse mutation | -       | 2.5 µg/ml           |
| *Salmonella typhimurium* TA1530, reverse mutation | N/T      | 372 µg/ml          |
| *Salmonella typhimurium* TA1535, reverse mutation | -       | 0.05 µg/ml         |
| *Salmonella typhimurium* TA1535, reverse mutation | -       | 167 µg/ml          |
| *Salmonella typhimurium* TA1535, reverse mutation | -       | 2500 µg/ml          |
| *Salmonella typhimurium* TA1537, reverse mutation | -       | 2500 µg/ml          |
| *Salmonella typhimurium* TA1538, reverse mutation | -       | 5000 µg/ml         |
| *Escherichia coli* WP2 uvrA, reverse mutation | -       | 5000 µg/ml          |
| *Escherichia coli* WP2 uvrA, reverse mutation | +       | 53 µg/ml          |
| *Escherichia coli* WP2 uvrA/pKM101 | -       | 5000 µg/ml          |
| *Escherichia coli* WP2 uvrA polA, reverse mutation | +       | 5.3 µg/ml          |
| **Gene conversion in yeast:**      |         |                     |
| *Saccharomyces cerevisiae* D7, gene conversion | +       | 25 µg/ml          |
| *Saccharomyces cerevisiae* JD1, gene conversion | -       | 250 µg/ml        |
| *Saccharomyces cerevisiae* PV-2 and PV-3, gene conversion | -       | 800 µg/ml        |
| *Saccharomyces cerevisiae* D7-144, gene conversion | +       | 0.8 µg/ml         |
| *Saccharomyces cerevisiae* PV4a and PV4b, homozygous | -       | 800 µg/ml         |
| *Saccharomyces cerevisiae* D5, forward mutation | +       | 30 µg/ml          |
| *Saccharomyces cerevisiae* D6 and D61-M, homozygosis | +       | 20 µg/ml          |
| *Saccharomyces cerevisiae* PV-1, forward mutation | -       | 800 µg/ml        |
| **DNA strand break:**              |         |                     |
| Syrian hamster embryo cell          | +       | 200 µg/ml          |
| F344 primary rat hepatocyte         | +       | 66 µg/ml           |
| Chinese hamster ovary cells         | +       | 3710 µg/ml          |
| Human bronchial epithelial cells    | +       | 200 µg/ml          |
| **Unscheduled DNA synthesis:**     |         |                     |
| F344 primary rat hepatocyte         | -       | 530 µg/ml          |
| Secondary cultures of human mammary epithelial cells | -       | 53 µg/ml          |
| **TK6 mutation assay:**             |         |                     |
| Human lymphoblast, tk locus         | -       | 40 µg/ml           |
| **HPRT assay:**                    |         |                     |
| Chinese hamster ovary cells         | +       | 200 µg/ml          |
| **Mouse lymphoma assay:**           |         |                     |
| LS178Y cells, tk locus              | +       | 100 µg/ml          |
| P388 F cells, tk locus              | +       | 161 µg/ml          |
| LS178Y cells, hprt locus            | ±       | 200 µg/ml          |
| **Gene mutation:**                 |         |                     |
| BALB/c 3T3 cells, Na⁺/K⁺ ATPase locus | N/T   | 40 µg/ml          |
| Human lymphoblastoid AHH-1 cells, hprt locus | + | 25 µg/ml          |
| **Sister chromatid exchange:**     |         |                     |
| Chinese hamster ovary cells         | ±       | 30 µg/ml          |
| Chinese hamster ovary cells         | -       | 106 µg/ml          |
| Rat liver RL4 cells                 | -       | 5 µg/ml           |
(astrocytes), but not in primary rat hepatocytes after incubation with acrylonitrile at v 2.5, 5, and 10 mM for 4 and 24 hrs, suggested a potentially critical role of oxidative stress in brain carcinogenesis. In male SD rats which received acrylonitrile in drinking water at 100 or 200 ppm 8-oxodeoxyguanosine, adducts were observed in the brain after 14 days of treatment, and at 50 ppm after 28 days of dosing. In the brain, oxidative damage correlated with persistent dose-dependent decrease in GSH to GSSG ratio and decrease in activities of catalase and superoxide dismutase and increase in lipid peroxidation. No effects were observed in the livers. Formation of 8-oxodeoxyguanosine was also increased in the brains of male SD and F344 rats exposed to carcinogenic doses of 30 and 300 ppm of acrylonitrile in drinking water for 21 days and in male SD rats administered acrylonitrile at 100 ppm in drinking water for 94 days. Dose-dependent increases in oxidative DNA damage were observed in white blood cells and brains of male SD rats exposed to 100 and 200 ppm of acrylonitrile in drinking water for 28 days. In the study by Jacob and Ahmed incubation of normal human astrocytes with up to 50 μM of acrylonitrile for 12 hrs did not produce any alterations. However, at higher dosages, 200 and 400 μM, acrylonitrile significantly affected viability of these cells, decreasing it up to 60%, with concomitant redox imbalance (depletion of GSH levels up to 35% lower than respective control) and increase in the formation of reactive species.

In primary glial cells of rats, induction of oxidative damage was also accompanied by significant depletion of GSH (93% decrease compared to the respective control) and enhancement of lipid peroxidation after incubation with 1.0 mM of acrylonitrile. In addition, due to depletion of GSH and shift to the oxidation pathway, glial cells were able to metabolize 1.0 mM of acrylonitrile to cyanide, which resulted in subsequent 90% reduction of ATP levels, in contrast to acute toxicity studies which could not obtain evidence of ATP depletion in the brain tissues of rats exposed to acrylonitrile, as reported above. Thus, oxidative damage in these cells can be enhanced by cytotoxicity.

Incubation of cultured rat astrocytes for up to 14 weeks with 0.25 mM of acrylonitrile provided clear evidence of oxidative damage to mitochondrial DNA in combination with functional mitochondrial changes, including alterations of mitochondrial membrane potential, which is one of the common markers of the neoplastic cell.

Caito et al. compared the responses of rat astrocytes and microglia to acrylonitrile dosing in vitro to address differential sensitivities and adaptive responses to acrylonitrile. Results indicated that acrylonitrile at 1 mM or less did not affect cell viability; that is, no cytotoxicity was observed, in either astrocytes or microglia, although microglia were more sensitive to acrylonitrile than astrocytes, accumulating less acrylonitrile while demonstrating higher levels of a lipid peroxidation by-product, F2-isoprostane. While astrocytes accumulated more acrylonitrile compared to microglial cells, they also exhibited higher levels of CYP2E1. Induction of nuclear factor-erythroid 2 related factor 2 (Nrf2), a key transcription factor involved in the

| Table 9. (continued) |
|--------------------------|--------------------------|-----------------------------|
| **Assay**                | Results                  | **Dose**                    |
| Human lymphoblast        | -                        | 26.5 μg/ml                  |
| Human bronchial epithelial cells | ±                        | 150 μg/ml                  |
| Chromosomal aberrations: |                         |                            |
| Chinese hamster ovary cells | +                        | 53 μg/ml                   |
| Chinese hamster lung cells | +                        | 6.2 μg/ml                  |
| Chinese hamster liver cells | +                        | 12.5 μg/ml                 |
| Rat liver RL4 cells      | -                        | 10 μg/ml                   |
| Human lymphocyte         | -                        | 5.3 μg/ml                  |
| Cell transformation assay: |                         |                            |
| BALB/c 3T3 Mouse cells   | +                        | 7 μg/ml                    |
| C3H 10T1/2 mouse cells   | +                        | 6.3 μg/ml                  |
| NIH/3T3 mouse cells      | +                        | 12.5 μg/ml                 |
| Syrian hamster embryo cells, clonal assay | + | 2 μg/ml |
| Syrian hamster embryo cells, focus assay | + | 50 μg/ml |
| Micronucleus assay:      |                         |                            |
| Chinese hamster ovary cells | +                        | 1600 μg/ml                 |

+, positive; ±, either positive or negative in several assays; -, negative; Fischer 344 rat strain; HID, highest ineffective dose; LEF, lowest effective dose; N/T, not tested; - S9, without metabolic activation; + S9, with metabolic activation; Data from ECHA 2018; IARC 1999; Walker et al. 2020a,b.
Table 10. Summary of findings for acrylonitrile in short term in vivo genotoxicity assays.

| Assay                                                                 | Results | Dose          |
|-----------------------------------------------------------------------|---------|---------------|
| Mutations in *Drosophila melanogaster*:                               |         |               |
| *D. melanogaster*, genetic crossing over or recombination             | -       | 805 mg/kg     |
| *D. melanogaster*, sex-linked recessive lethal mutations              | -       | 3500 ppm      |
| *D. melanogaster*, somatic mutation                                   | +       | 265 mg/kg     |
| *D. melanogaster*, aneuploidy                                         | +       | 2.7 ppm       |
| Comet assay:                                                          |         |               |
| Rat stomach                                                           | -       | 62.5 mg/kg    |
| Rat liver                                                             | +       | 62.5 mg/kg    |
| Rat brain                                                             | -       | 100 ppm       |
| Rat Zymbal’s gland                                                    | -       | 100 ppm       |
| Wild type mouse forestomach                                            | +       | 2.5 mg/kg     |
| CYP2E1-null mouse forestomach                                          | -       | 60 mg/kg      |
| Wild type/CYP2E1-null mouse stomach                                   | -       | 20/60 mg/kg   |
| Wild type mouse liver                                                 | +       | 10 mg/kg      |
| CYP2E1-null mouse liver                                               | -       | 60 mg/kg      |
| Wild type/CYP2E1-null mouse Harderian gland                           | -       | 20/60 mg/kg   |
| Wild type/CYP2E1-null mouse lung                                      | -       | 20/60 mg/kg   |
| Wild type mouse ovary                                                 | +       | 20 mg/kg      |
| CYP2E1-null mouse ovary                                               | +       | 10 mg/kg      |
| Unscheduled DNA synthesis:                                            |         |               |
| Rat gastric mucosa                                                    | +       | 23 mg/kg      |
| SD rat lung                                                           | ±       | 46.5 mg/kg    |
| F344 rat hepatocytes                                                  | +       | 50 mg/kg      |
| F344 rat hepatocytes                                                  | -       | 75 mg/kg      |
| F344 rat spermatocytes                                                | -       | 75 mg/kg      |
| SD rat spermatocytes                                                  | ±       | 46.5 mg/kg    |
| F344 rat brain                                                        | -       | 50 mg/kg      |
| HPRT assay:                                                           |         |               |
| F344 rat splenic T-cells                                              | +       | 21 mg/kg      |
| F344 rat thymus and splenic T-cells                                   | +       | 224 mg/kg     |
| B6C3F1 mice thymus and splenic T-cells                               | +       | 58 mg/kg      |
| lacZ transgenic mice thymus and splenic T-cells                       | +       |               |
| Sister chromatid exchange:                                            |         |               |
| C57BL/6 mouse bone marrow                                            | ±       | 45 mg/kg      |
| C57BL/6 mouse bone marrow                                            | -       | 60 mg/kg      |
| Chromosomal aberrations:                                             |         |               |
| Mouse bone marrow                                                    | -       | 140 mg/kg     |
| Mouse, spermatogonia                                                 | -       | 140 mg/kg     |
| C57BL/6 mouse bone-marrow                                            | -       | 30 mg/kg      |
| Swiss albino mouse bone marrow                                        | -       | 40 mg/kg      |
| SD rat bone marrow                                                   | -       | 40 mg/kg      |
| Micronucleus assay:                                                   |         |               |
| Mouse bone marrow                                                    | -       | 30 mg/kg      |
| Wild type/CYP2E1-null mouse erythrocytes                              | -       | 20/60 mg/kg   |
| Dominant lethal test:                                                 |         |               |
| Male mice                                                            | -       | 140 mg/kg     |
| Male F344 rats                                                       | -       | 60 mg/kg      |

+, positive; ±, either positive or negative in several assays; -, negative; HID, highest ineffective dose; Fischer 344 rat strain; LEF, lowest effective dose; SD, Sprague-Dawley rat strain; Data from ECHA 2018²; IARC 1999⁸; Walker et al. 2020a,b,²²,²³
response to oxidative stress was also observed in rat microglia, but not in astrocytes in rats and mice or glial cells in mice.\textsuperscript{19,21} GSH levels were up-regulated in both rat cell types, microglia, and astrocytes, evidencing a protective mechanism against acrylonitrile-associated oxidative stress. These data suggest that microglia and astrocytes exhibit no direct cytotoxicity, but have different sensitivities and responses to acrylonitrile, which are linked to the intracellular thiol status intrinsic to each of these two cell types.

Evidence of oxidative DNA damage in rodents was mainly observed in a target tissue for carcinogenicity, brain, while in other target organs, Zymbal’s gland, Harderian gland, and in cells from a non-target organ, liver, it was not detected.\textsuperscript{23,24,145} These findings can be attributed to the lower antioxidant capacity of rat brain compared to the liver. Difference in expression of GST isoforms between the brain and other tissues\textsuperscript{140,156} might also play a role in the formation of oxidative stress predominantly in the brain. Such selectivity can indicate the importance of oxidative damage in the development of brain neoplasia, while in other target organs other mechanisms may be involved. For example, damage produced by acrylonitrile in the forestomach was suggested to involve activation of neutrophils and an increase in myeloperoxidase activity, which subsequently stimulated acrylonitrile biotransformation to cyanide.\textsuperscript{151} Also, depletion of GSH in combination with release of tissue-damaging radicals from neutrophils can exacerbate tissue damage.

In addition to cytotoxicity, the accumulation of reactive oxygen species can induce an inflammatory response in both astrocytes and microglia, activating expression of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and p53 transcription factors in primary microglia and astrocytes exposed to 0.1, 0.5, or 1 mM acrylonitrile for 3 or 7 days. Subsequently, secreted inflammatory mediators showed different patterns between the two cell lines, suggesting difference in inflammatory response.\textsuperscript{20} In rat brain acrylonitrile administration, in addition to producing an inflammatory response, triggered activation of cyclins responsible for cell proliferation and inhibition of pro-apoptotic genes.\textsuperscript{152} These effects were prevented by dietary supplementation with antioxidants.

Primary glial cells isolated from cortical tissue of neonatal C57BL/6J mice were resistant to acrylonitrile-induced oxidative stress, which could contribute to species-specific response to chronic acrylonitrile administration.\textsuperscript{21} Mice were more resistant to chronic administration of acrylonitrile, showing a decrease in survival only at dose levels close to the LD$_{50}$. Moreover, the brain glial tumors observed in rats of both sexes, were absent in mice, which were administered higher (up to 3 times) doses of acrylonitrile. This could be explained by inter-species differences in dynamic properties of the organ. Glial cells in mice were more resistant than in rats to oxidative damage produced by acrylonitrile, possibly since mice clear CEO faster,\textsuperscript{72–74} thereby reducing CEO concentration in the brain by half.\textsuperscript{61,79} Moreover, in rats, CEO concentration in the brain was almost double that of blood. This may explain, in part, the lack of brain neoplasia in mice, which in general are less susceptible to brain neoplasia.\textsuperscript{48}

In cell suspensions prepared from the spleens of C57/Bl6 female mice, acrylonitrile inhibited proliferation of T- and B-lymphocytes, with a greater effect on the B-cells, while not affecting their viability.\textsuperscript{153} According to the authors this might create a favorable condition for carcinogenicity. In an earlier study by Hamada et al.\textsuperscript{154} acrylonitrile also produced an immunosuppressive effect in CD-1 mice, decreasing the number of IgA producing cells in the intestines and a significant depletion of spleen lymphocyte population, which could be a contributing factor to the carcinogenicity of acrylonitrile in the forestomach.

Some epigenetic effects could also contribute to acrylonitrile carcinogenicity.\textsuperscript{8} Thus, in rat DITNC1 cell line, acrylonitrile produced a dose-dependent inhibition of gap junctional intercellular communication in following 2-hour treatment with 0.10 mmol/L and 1 mmol/L, which was absent in primary cultured rat hepatocytes.\textsuperscript{155} This effect was alleviated by co-incubation of astrocytes with vitamin E or 2-oxothiazolidine-4-carboxylic acid, which is a precursor to glutathione synthesis. Li and colleagues\textsuperscript{156} using Jurkat cell lines reported that acrylonitrile can produce immunotoxicity by damaging separation of lipid raft, structures of cell membrane present in leukocytes which are involved in cell signal transduction and restraining Ras-Raf-MAPK-ERK signaling pathways. While this evidence is compelling, data supporting an epigenetic MoA, in particular in vivo, is currently lacking.

**Discussion**

**Suggested Mechanisms of Acrylonitrile Carcinogenicity**

The reviewed information available in the literature supports the conclusion that acrylonitrile is a highly toxic carcinogen with a complex MoA for tumorigenicity which may involve multiple mechanisms. The biological significance of DNA binding of acrylonitrile for the carcinogenic MoA of the compound is questionable, since, in contrast to in vitro studies, no promutagenic etheno-adducts were observed in vivo, and N7-OEG adducts were observed in tissues that were not targets for carcinogenicity, for example, liver. Moreover, acrylonitrile in vivo exhibited at most weak mutagenic potential even at concentrations that were above tumorigenic doses. The applicability of genotoxicity findings in the in vitro assays is of questionable relevance to hazard assessment, since in vivo results in the target tissues were mainly negative, and in some studies in
which genotoxicity was detected, it was observed in non-target tissues for carcinogenicity, for example, liver. Thus, acrylonitrile carcinogenicity is not likely to stem from direct DNA damage. One of the most extensively reported mechanisms of acrylonitrile carcinogenicity was production of oxidative DNA damage, which can induce a combination of both genotoxic and epigenetic effects, cytotoxicity and consequent sustained inflammatory response.

Regarding brain and forestomach tumorigenicity, neurotoxicity and ulcers of forestomach mucosa were commonly observed effects of acute and subchronic toxicity of acrylonitrile, associated with depletion of glutathione. Moreover, oxidation of acrylonitrile can lead to production of a reactive metabolite CEO, and a cytotoxic metabolite cyanide, both of which were associated with adverse effects found in various studies. In addition, acrylonitrile, cyanide, and CEO can penetrate the blood-brain barrier, accumulating in the target tissue.

The four target sites of acrylonitrile carcinogenicity in the six bioassays were in tissues, which are located at the interface of different microenvironments and provide a barrier protection from injury or stress. The absence of response of other barrier tissues (e.g., lung) could reflect chemical kinetic (e.g., different metabolism of acrylonitrile) and dynamic factors and inherent tumor susceptibility. All of the target tissues are composed of parenchymal and non-parenchymal cellular elements. The predominant cellular component of the induced brain neoplasia was a non-parenchymal component (microglia), whereas in the other three tissues the predominant cellular component was parenchymal. When the integrity of a tissue is compromised, for example, injury to the forestomach wall, the parenchymal cellular elements respond predominantly with regenerative compensatory proliferation to correct the tissue perturbation. The integument-associated tissues undergo similar processes, which protect the auditory (Zymbal’s gland) or ocular orbital (Harderian gland) regions. In the blood-brain barrier tissue (region), the microglia, which is a non-parenchymal cellular component derived from macrophage precursor, plays a predominant role in response to stress and injury to neural cells produced by neurotoxins. 

Unlike astrocytes, which previously were considered to be the target cells of acrylonitrile carcinogenicity, microglia cells can readily undergo proliferation in response to pro-inflammatory signaling or, in case of depletion, recolonization. Microglial cells activated in response to neurotoxins by classical M1 activation, release more pro-inflammatory mediators and reactive oxygen species, exacerbating tissue damage.

Hyperplastic changes in the Harderian gland were observed in mice after administration of various chemicals. Since this gland is also considered to be a site of immune response, among other functions, it is possible that cell proliferation observed in the gland could be a result of immune response activation.

As evident from available extensive chemokinetic data, the rodent target organs of acrylonitrile carcinogenicity were exposed to acrylonitrile and CEO in a dose-proportional manner. However, the mouse eliminated acrylonitrile and CEO faster, resulting in levels of CEO which were higher in rat blood and brain compared to respective mouse levels. This could contribute to the lack of brain tumors in mice.

Tissue- and species-specific induction of oxidative stress and subsequent inflammation is a likely MoA for brain tumor development in rats, while in the forestomach, direct cytotoxicity of acrylonitrile and its metabolite cyanide together with immunosuppression might be more relevant (Figure 3). For the Zymbal’s and Harderian glands, mechanistic studies investigating a potential acrylonitrile MoA are lacking, although absence of direct and oxidative DNA damage in the Zymbal’s gland after acrylonitrile administration was reported. Sustained stress and cytotoxicity produced by acrylonitrile possibly can be involved in carcinogenicity in these two tissues.

Depletion of GSH after prolonged exposure to a high concentration of acrylonitrile is a potential initiating event in acrylonitrile MoA (Figure 3). Decrease of the detoxification route and the presence of an oxidation route of acrylonitrile metabolism permits increased formation of two metabolites, reactive CEO, as well as cytotoxic cyanide. This could lead to accumulation of oxygen-derived free radicals and mitochondrial damage leading to ATP depletion, as shown with long-term exposure of rat astrocytes and glial cells to acrylonitrile.

Also, oxidative stress is exacerbated by depletion of GSH, which has antioxidant properties. Cytotoxicity and increased oxidative stress may contribute to tissue injury, particularly in the brain, which lacks a lymphatic vascular system. Production of pro-inflammatory mediators induces inflammatory conditions, which can lead to further cell and tissue injury and death or apoptosis of contiguous cells. Subsequently, local tissue immunocytes (e.g., microglia and other histiocytes) are recruited. The extent of immunocyte recruitment differs from site to site. In the case of microglia, immunocyte involvement is significant. In response to the injury, cells undergo compensatory regenerative cell proliferation (hyperplasia), which was observed in all target organs of carcinogenicity with chronic dosing (Tables 3–7). Such prolonged administration of an injurious agent leads to cell proliferation, and in turn, proliferating cells can transform and progress to neoplasia, as reported with numerous other chemical carcinogens. To support this hypothesis, time course studies are needed.

It is possible that in addition to direct and indirect cytotoxicity of acrylonitrile and oxidative stress, neoplastic conversion of the target cells can develop through the
induction of cell proliferation signals leading to increased DNA synthesis, in combination with inhibition of an apoptosis signal, as reported by Pu et al.\textsuperscript{152} Again, mechanistic studies are required to support this hypothesis.

A direct local injurious effect of acrylonitrile dosing may occur in the forestomach barrier site (the portal of entry of acrylonitrile in five of the six bioassays), where neoplasia developed in both rodent species of both sexes in a similar dose and time-related fashion. Injury was evident by formation of erosions of the forestomach as well as hyperplasia/hyperkeratosis of forestomach and glandular stomach mucosa, which were also observed after a shorter duration of administration of acrylonitrile. In the other systemically accessible sites, the species differences in the permeability of the tissue and the speed of acrylonitrile clearance may have influenced development of the neoplastic response, that is, the absence of brain and Zymbal’s gland tumors in mice and Harderian gland tumors in rats.

The combination of the different sustained stresses, which occurred across species, strains, and sexes, was exacerbated in some studies by a significant chronic reduction in water intake. This was pronounced in all drinking water studies in rats (Table 2), likely resulting from poor palatability. Reduced food consumption and consequent body weight gain reduction in a dose and time-dependent fashion contributed to compromised survival. It is possible that water-electrolyte imbalance induced by hypohydration and malnutrition could have a co-carcinogenic effect, although, specific evidence supporting this hypothesis is lacking. In the oral gavage and inhalation studies, water intake was increased, indicating better tolerability. Nevertheless, the authors reported that acrylonitrile produced kidney toxicity, which could have exacerbated water-electrolyte imbalance.

The above suggested MoAs are based on extensive data, but a definitive MoA for acrylonitrile carcinogenicity in the four primary target tissues has not been established. For Zymbal’s and Harderian glands, evidence to conduct a WoE evaluation is limited or missing. The postulated MoAs should be further investigated by short-term \textit{in vivo} experiments in both rats and mice, including evaluation of genomic profiles in target tissues. Other key events, such as epigenetic alterations and receptor modulations, also warrant investigation. In addition, biological consequences of covalent binding of acrylonitrile to proteins are not well understood; thus, it would be important to identify the relationship between protein adducts and potential alterations of protein function and their effect on signaling networks.

\textbf{Weight of evidence evaluation for acrylonitrile MoA}

The US EPA/IPCS animal MoA guidance\textsuperscript{33} was applied to two of the target tissues of acrylonitrile carcinogenicity, forestomach and brain, to evaluate weight of evidence for MoAs of acrylonitrile carcinogenicity suggested above (Table 11).

1. Biological concordance: The hypothesized MoA does not conflict with the broader biological knowledge. Although, the contribution of GSH depletion to chemical-mediated carcinogenicity is not established, it is known that GSH plays an important role in the detoxication of xenobiotics and protects tissues from oxidative stress. On the other hand, sustained cytotoxicity that was associated with glutathione depletion by acrylonitrile in gastric tissue and brain and resulting compensatory cell proliferation is a well-established MoA for many chemical carcinogens.\textsuperscript{163}

2. Essentiality of key events: Cytotoxicity of acrylonitrile was prevented by depletion of CYP2E1 enzyme and by supplementation of sulfhydryl compounds. Thus, no toxicity was observed in CYP2E1 knockout mice administered acrylonitrile, while in rats, induction of CYP2E1 enzyme exacerbated acrylonitrile toxicity. Depletion of GSH showed strong correlation with accumulation of cyanide in various tissues. In addition, GSH depletion correlated with forestomach mucosa toxicity and oxidative DNA damage in brain.

3. Concordance of empirical observations among key events (dose-response, temporality, incidence): Reduction of GSH levels after acrylonitrile administration was shown to be dose- and time-dependent. Both target organs for acrylonitrile carcinogenicity, forestomach and brain, demonstrated limited capacity to recover depleted GSH. Mice, which metabolize acrylonitrile faster, developed forestomach tumors at lower doses compared to rats. Progression from cytotoxicity to hyperplastic changes of the glandular mucosa of the stomach that correlated with GSH depletion was observed in many subchronic and chronic studies at dosages comparable to those at which tumors or acute toxicity signs were observed. In the brain, cytotoxicity caused by oxidative damage which correlated with GSH depletion was also observed in a dose-dependent manner. However, in the chronic carcinogenicity bioassay, a temporal relationship between glial cell proliferation and incidences of brain tumors was not clearly defined.

4. Consistency: Toxicity of acrylonitrile to the gastrointestinal tract and central nervous system was reported in multiple acute, subacute, subchronic, and chronic studies in rodents. Evidence of oxidative stress after acrylonitrile exposure was demonstrated in the brain of rats in several studies.

5. Analogy: Regarding the forestomach neoplasms, a variety of other chemicals that produce cytotoxicity in the forestomach have produced an increase in
neoplasia in that tissue, that is, butylated hydroxyanisole, ethyl acrylate, and sesamol. Concerning the brain tumors, no other tumorigen for this tissue has been associated with oxidative DNA damage. Nevertheless, oxidative DNA damage has been found in other target tissues, for example, lung or liver, for other carcinogens, for example, pentachlorophenol, arsenic, phenobarbital. In addition, oxidative damage has been implicated in production of neurotoxicity by several chemotherapeutic agents, such as cisplatin. Thus, the suggested MoA would be anticipated in rodents.

**Human biological plausibility**

The lack of relevance to human cancer hazard for a variety of rodent tumor responses is discussed by Williams et al. Evaluation of possible MoAs for acrylonitrile in all four target tumor sites in rodents (Figure 3), as well as assessment of acrylonitrile using the key characteristics of carcinogens for use in hazard assessment (Table 12), supports the conclusion that the human relevance of the induction of these tumors is doubtful. While direct and indirect (via oxidative damage) DNA damage is known to occur in humans, a lack of relevance of the acrylonitrile-induced tumors in rats and mice to humans and differences in metabolism of acrylonitrile between rodents and humans provides little support for human hazard. Moreover, current human chronic exposures to acrylonitrile in occupational settings are much lower compared to the carcinogenic doses in rodents.

Symptoms of acrylonitrile toxicity in workers were associated with high blood levels of cyanide ranging from 1.9 mg/L to 4.3 mg/L, suggesting that oxidative metabolism of acrylonitrile in humans is more active compared to rodents. However, under environmentally-relevant low-dose exposures, acrylonitrile metabolism to CEO is limited by liver blood flow and alveolar ventilation rate rather than intrinsic rate of metabolism.

Another important species difference in the metabolism of acrylonitrile is the presence of genetic polymorphism in human population. Investigation of hemoglobin adducts associated with acrylonitrile exposure suggested that in humans GSTP1 is more important for detoxification of acrylonitrile compared to GSTM1 subunit which is selective for acrylonitrile binding in rats and potential role of variation in GST genotypes might play a role in susceptibility of humans to acrylonitrile toxicity. Specifically, polymorphism of the GSTP1 and GSTT1, which is associated with deficient conjugation, might play a role. No significant influences of CYP2E1 polymorphism were found on acrylonitrile-specific hemoglobin adduct levels in humans, except for a trend pointing to higher levels of adducts with the A-316G mutations, nevertheless, slower metabolism of acrylonitrile via CYP2E1-mediated pathway could be associated with higher adduct levels.

Three of the target tissues, that is, forestomach and Harderian gland (both present in rats and mice) and Zymbal’s gland (present and described commonly in rats, but only in a vestigial form in mice), are absent in humans. Of these three target tissues, applying data on rodent forestomach tumors (occurring in both sexes of rats and mice) to the prediction of cancer risk in humans has been a particularly controversial aspect of interspecies extrapolation. Since the forestomach is lined with squamous epithelium similar to the pharynx and esophagus, some argue that forestomach tumors in rodents may be relevant to human hazard. Acrylonitrile does not have this property. Additionally, the most relevant exposure route in humans is inhalation and not the alimentary route. No increase in forestomach tumors was observed in the carcinogenicity bioassay with acrylonitrile administration by inhalation, indicating a role for direct contact.

### Table 11. Weight of evidence analysis for acrylonitrile MoAs.

| Evolved Bradford Hill considerations | Forestomach | Brain |
|-------------------------------------|-------------|-------|
| Biological concordance              | +           | +     |
| Essentiality of key events          | +           | +     |
| Concordance of empirical observations| +           | +     |
| Dose–response relationships among key events | +       | +     |
| Temporality among key events        | +           | ±     |
| Incidence between key events and end (adverse) effects | +       | +     |
| Consistency                         | +           | +     |
| Analogy                             | +           | ±     |

+, supporting data; ±, inconsistent data; -, missing data.

*Adapted from Meek et al. 2014*
Table 12. Summary of evidence for key characteristics of carcinogen based on mechanistic data for acrylonitrile described in literature.

| Key characteristic                        | Fore stomach | Brain   | Zymbal’s gland | Harerial gland | Other tissues |
|------------------------------------------|--------------|---------|----------------|----------------|--------------|
| Is electrophilic or can be metabolically activated | + in vitro  | +       | N/R            | N/R            | + (liver)    |
| Is genotoxic                             | + in vitro   | + in vivo| - in vivo      | - in vivo      | + in vitro   |
| Alters DNA repair or causes genomic instability | N/R  | N/R     | N/R            | N/R            | ± in vivo    |
| Induces epigenetic alterations           | N/R          | N/R     | N/R            | N/R            | N/R         |
| Induces oxidative stress                 | N/R          | N/R     | N/R            | N/R            | - (liver)    |
| Induces chronic inflammation             | +            | +       | N/R            | N/R            | +           |
| Is immunosuppressive                     | N/R          | N/R     | N/R            | N/R            | + (spleen)  |
| Causes immortalization                   | N/R          | N/R     | N/R            | N/R            | N/R         |
| Alters cell proliferation, cell death, nutrient supply | ± | +     | N/R            | N/R            | N/R         |

+, positive; ±, equivocal; -, negative; N/R, evidence not reported.

Adapted from Smith et al. 2016.31

In contrast to observations of acrylonitrile-associated brain tumors in several rat bioassays,13,14 none of several epidemiological studies reported increases in brain tumors in populations exposed to acrylonitrile in occupational settings.5,6,10–12 The acrylonitrile-associated brain tumors in rats were initially diagnosed by conventional histopathology as gliomas derived from astrocytes (astrocytomas). Re-examination of these tumors utilizing immunohistochemical markers revealed that they were primarily composed of microglia,18 components of glia that function as macrophages and are important for the maintenance of the blood-brain barrier. In humans, the most common malignant primary brain tumor is glioblastoma, which is primarily derived from the astrocytic lineage.174–176 While microglia represent a major non-neoplastic component of gliomas,158 presently, only two cases of true microglioma in humans have been reported.174,177 This difference in cellular susceptibility may explain the absence of central nervous system carcinogenicity of acrylonitrile in humans.178 Thus, in an evaluation of carcinogenic risk to humans, IARC27 found that the evidence for the carcinogenicity of acrylonitrile was very limited, with brain tumors being highly infrequent in the epidemiological studies. In addition, the human blood-brain barrier offers more effective protection from toxins compared to either rats or mice.179,180

No macroscopic or histologic changes in the lungs were observed in rats in a 2-year inhalation study of acrylonitrile, although degenerative and inflammatory changes in the nasal passages were observed.39 As mentioned above, a slight increase in combined incidences of alveolar/bronchiolar adenoma or carcinoma that may have been related to acrylonitrile exposure was observed only in female mice and was not dose dependent.15,16 In humans, while some studies detected an association between acrylonitrile exposure and increased risk of lung cancer in humans,35 others have shown that these findings are unsupported based on the absence of dose-response and lack of proper adjustments for confounding factors, such as smoking.4

Currently, the occupational exposure levels to acrylonitrile are estimated to be below 2 ppm.7,28 Assuming that the highest allowed occupational exposure to acrylonitrile is 2 ppm or 4.3 mg/m³ for 8-hours over a 40-hour work week,28,30 an average of 261 workdays per year and work duration of 10 years, an average lifetime daily exposure to acrylonitrile is estimated to be 146.4 μg/m³ (lifetime daily exposure = 4.3 mg/m³ x (8/24) hrs x (261/365) days x (10/70) years). Using the inhalation cancer unit risk factor of 1.02 × 10⁻⁶ per μg/m³ calculated above based on the animal data, an estimated excess lifetime cancer risk from acrylonitrile exposure is 1.49 × 10⁻⁴ (risk = 146.4 μg/m³ x (1.02 × 10⁻⁶ per μg/m³)) or approximately 0.015%, which is negligible. Even when calculations are corrected for a 40-year career-long occupational exposure, the lifetime cancer risk does not exceed 0.06%.

In conclusion, the suggested MoA of acrylonitrile carcinogenicity in rodents is consistent with direct and indirect (due to oxidative damage) cytotoxicity, and compensatory cell proliferation, although weak, likely indirect, mutagenicity cannot be ruled out. Overall, the relevance to humans of findings with acrylonitrile in rodent studies is questionable and requires further dose-effect and mechanistic investigation. Combined with the largely negative epidemiology in humans and margin of exposure, human risk is unlikely.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Funding was provided by the Global Acrylonitrile Product Stewardship. The authors certify that their freedom to design, conduct, interpret, and publish research was not compromised by the sponsor.

ORCID iD
Tetyana Kobets https://orcid.org/0000-0002-8207-5035

Supplemental material
Supplemental material for this article is available online.

References
1. European Union Risk Assessment Report (EU RAR). Acrylonitrile. CAS No: 107-13-1. EINECS No: 203-466-5. 1st priority list. EUR 20857 EN, vol. 32. Ispra, Italy: European Chemicals Bureau, European commission, Joint Research Centre, Institute for Health and Consumer Protection, 2004.
2. International Agency for Research on Cancer (IARC). Acrylonitrile. Reevaluation of some organic chemicals, hydrazine and hydrogen peroxide, 71. Lyon, France: IARC Monogr Eval Carcinog Risks Hum, 1999, pp. 43–108.
3. European Chemicals Agency (ECHA). Background document in support of the Committee for Risk Assessment (RAC) evaluation of limit values for acrylonitrile in the workplace. ANNEX 1. ECHA/RAC/O-0000001412-86-188/F. Helsinki, Finland: European Chemicals Agency, 2018.
4. Alexander DD, Pastula ST and Riordan AS. Epidemiology of lung cancer among acrylonitrile-exposed study populations: a meta-analysis. Regul Toxicol Pharmacol 2021; 122: 104896.
5. Benn T and Osborne K. Mortality of United Kingdom acrylonitrile workers–an extended and updated study. Scand J Work, Environ Health 1998; 24(Suppl 2): 17–24.
6. Blair A, Stewart PA, Zaebst DD, et al. Mortality of industrial workers exposed to acrylonitrile. Scand J Work, Environ Health 1998; 2(Suppl 2): 25–41.
7. Cole P, Mandel JS and Collins JJ. Acrylonitrile and cancer: a review of the epidemiology. Regul Toxicol Pharmacol 2008; 52: 342–351.
8. Haber LT and Patterson J. Report of an independent peer review of an acrylonitrile risk assessment. Hum Exp Toxicol 2005; 24: 487–527.
9. Marsh GM and Zimmerman SD. Mortality among chemical plant workers exposed to acrylonitrile. J Occup Environ Med 2015; 57: 134–145.
10. Muto T, Sakurai H, Omae K, et al. Health profiles of workers exposed to acrylonitrile. Keio J Med 1992; 41: 154–160.
11. Swaen GMH, Bloemen LJJN, Twisk J, et al. Mortality update of workers exposed to acrylonitrile in The Netherlands. J Occup Environ Med 2004; 46: 691–698.
12. Wood SM, Buffle PA, Burau K, et al. Mortality and morbidity of workers exposed to acrylonitrile in fiber production. Scand J Work, Environ Health 1998; 24(Suppl 2): 54–62.
13. Bigner DD, Bigner SH, Burger PC, et al. Primary brain tumours in Fischer 344 rats chronically exposed to acrylonitrile in their drinking-water. Food Chem Toxicol 1986; 24: 129–137.
14. Johansson FR and Levinskas GJ. Chronic toxicity and oncogenic dose-response effects of lifetime oral acrylonitrile exposure to Fischer 344 rats. Toxicol Lett 2002; 132: 221–247.
15. Ghanayem BI, Nyska A, Haseman JK, et al. Acrylonitrile is a multisite carcinogen in male and female B6C3F1 mice. Toxicol Sci 2002; 68: 59–68.
16. National Toxicology Program (NTP). Toxicology and carcinogenesis studies of acrylonitrile (CAS No. 107-13-1) in B6C3F1 mice (gavage studies). NTP TR. Research Triangle Park, NC: Public Health Service, US Department of Health and Human Services. National Institute of Environmental Health Sciences, 2001, 506.
17. Meek ME, Bucher JR, Cohen SM, et al. A framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol 2003; 33: 591–653.
18. Kolenda-Roberts HM, Harris N, Singletary E, et al. Immunohistochemical characterization of spontaneous and acrylonitrile-induced brain tumors in the rat. Toxicologic Pathol 2013; 41: 98–108.
19. Cai to S, Yu Y and Aschner M. Differential response to acrylonitrile toxicity in rat primary astrocytes and microglia. Neurotoxicology 2013; 37: 93–99.
20. Cai to SW, Yu Y and Aschner M. Differential inflammatory response to acrylonitrile in rat primary astrocytes and microglia. Neurotoxicology 2014; 42: 1–7.
21. Cai to S, Park M and Aschner M. Resistance of mouse primary microglia and astrocytes to acrylonitrile-induced oxidative stress. Neurotoxicology 2017; 63: 120–125.
22. Walker VE, Fennell TR, Walker DM, et al. Analysis of DNA adducts and mutagenic potency and specificity in rats exposed to acrylonitrile. Chem Res Toxicol 2020; 33: 1609–1622.
23. Walker VE, Walker DM, Ghanayem BI, et al. Analysis of biomarkers of DNA damage and mutagenicity in mice exposed to acrylonitrile. Chem Res Toxicol 2020; 33: 1623–1632.
24. Williams GM, Kobets T, Duan J-D, et al. Assessment of DNA binding and oxidative dna damage by acrylonitrile in two rat target tissues of carcinogenicity: implications for the mechanism of action. Chem Res Toxicol 2017; 30: 1470–1480.
25. Williams G, Iatropoulos M, Enzmann H, et al Carcinogenicity of chemicals: assessment and human extrapolation. In: Hayes AW and Kruger CL (eds) Hayes’ principles and methods of toxicology. 6th ed.. Philadelphia, PA: CRC Press, Taylor and Francis; 2014, pp. 1251–1304.
26. International Agency for Research on Cancer (IARC). Some monomers, plastics and synthetic elastomers, and acrolein. Lyon, France: IARC Monogr Eval Carcinog Risks Hum, 1979, pp. 73–113.

27. International Agency for Research on Cancer (IARC). Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42, 7(Suppl 7). Lyon, France: IARC Monogr Eval Carcinog Risks Hum, 1987, pp. 1–440.

28. Occupational Safety and Health Administration (OSHA). US Department of Labor. Occupational safety and health standards. Acrylonitrile; CASRN 107-13-1. Washington, DC: Occupational Safety and Health Administration, 2017. https://www.osha.gov/pls/oshaweb/owadisp.show_document?p_id=100658&p_table=STANDARDS (accessed 21 November 2021).

29. US Environmental Protection Agency (US EPA). Integrated Risk Information System (IRIS) chemical assessment summary. Acrylonitrile; CASRN 107-13-1. Washington, DC: U.S. Environmental Protection Agency. National Center for Environmental Assessment, 1991.

30. US Environmental Protection Agency (US EPA). Integrated Risk Information System (IRIS) Chemical Assessment Summary. Acrylonitrile; CASRN 107-13-1. Washington, DC: U.S. Environmental Protection Agency. National Center for Environmental Assessment, 2006. https://cfpub.epa.gov/ncea/iris/iris_documents/documents/subst/0206_summary.pdf (accessed 4 November 2021).

31. Smith MT, Guyton KZ, Gibbons CF, et al. Key characteristics of carcinogens as a basis for organizing data on mechanisms of carcinogenesis. Environ Health Perspect 2016; 124: 713–721.

32. Becker RA, Dreier DA, Manibusan MK, et al. How well can carcinogenicity be predicted by high throughput “characteristics of carcinogens” mechanistic data? Regul Toxicol Pharmacol 2017; 90: 185–196.

33. Meek ME, Palermo CM, Bachman AN, et al. Mode of action human relevance (species concordance) framework: Evolution of the Bradford Hill considerations and comparative analysis of weight of evidence. J Appl Toxicol 2014; 34: 595–606.

34. Bakker J, Jongen SMJ, van Neer FCJ, et al. Occupational contact dermatitis due to acrylonitrile. Contact Dermatitis 1991; 24: 50–53.

35. Koutros S, Lubin JH, Graubard BI, et al. Extended mortality follow-up of a Cohort of 25,460 workers exposed to acrylonitrile. Am J Epidemiol 2019; 188: 1484–1492.

36. National Toxicology Program (NTP). Report on carcinogens. 14th edition. Research Triangle Park, NC: U.S. Department of Health and Human Services, Public Health Service, 2016. https://ntp.niehs.nih.gov/go/roc14 (accessed 4 November 2020).

37. Johannsen FR and Levinskas GJ. Comparative chronic toxicity and carcinogenicity of acrylonitrile by drinking water and oral intubation to Spartan Sprague-Dawley rats. Toxicol Lett 2002; 132: 197–219.

38. Quast JF. Two-year toxicity and oncogenicity study with acrylonitrile incorporated in the drinking water of rats. Toxicol Lett 2002; 132: 153–196.

39. Quast F, Schuetz MF and Balmer TS. A two-year toxicity and oncogenicity study with acrylonitrile following inhalation exposure of rats. Report. Midland, MI: Dow Chemical Co., Toxicology Research Laboratory, 1980.

40. Gallagher GT, Mauil EA, Kovacs K, et al. Neoplasms in rats ingesting acrylonitrile for two years. J Am Coll Toxicol 1988; 7: 603–615.

41. Maltoni C, Ciliberti A, Cotti G, et al. Long-term carcinogenicity bioassays on acrylonitrile administered by inhalation and by ingestion to Sprague-Dawley rats. Ann New York Acad Sci 1988; 534: 179–202.

42. National Toxicology Program (NTP). NTP historical controls report. All routes and vehicles. F 344/N rats. Washington, DC: National Toxicology Program, 2011. https://ntp.niehs.nih.gov/ntp/historical Controls/ntp2000_2011/histcom2011_rats_allroutes.pdf (accessed 23 July 2021).

43. National Toxicology Program (NTP). NTP historical controls report. All routes and vehicles. Harlan Sprague-Dawley rats. Washington, DC: National Toxicology Program, 2020. https://ntp.niehs.nih.gov/ntp/historical Controls/ntp2000_2020/r_hcrpt_allrte20201200.pdf (accessed 23 July 2021).

44. National Toxicology Program (NTP). NTP historical controls report. All routes and vehicles. Mice. Washington, DC: National Toxicology Program, 2020. https://ntp.niehs.nih.gov/ntp/historical Controls/ntp2000_2020/m_hcrpt_allrte20201200.pdf (accessed 23 July 2021).

45. Dinse GE, Peddada SD, Harris SF, et al. Comparison of NTP historical control tumor incidence rates in female Harlan Sprague Dawley and Fischer 344/N Rats. Toxicologic Pathol 2010; 38: 765–775.

46. International Agency for Research on Cancer (IARC). Predictive value of rodent fore stomach and gastric neuroendocrine tumors in evaluating carcinogenic risks to humans, views and expert opinions of an IARC Working Group. Technical Publication No. 39. Lyon, France: International Agency for Research on Cancer, 2003.

47. Ghanyem BI, Maronpot RR and Matthews HB. Association of chemically induced forestomach cell proliferation and carcinogenesis. Cancer Lett 1986; 32: 271–278.

48. Weber K, Garman RH, Germann P-G, et al. Classification of neural tumors in laboratory rodents, emphasizing the rat. Toxicologic Pathol 2011; 39: 129–151.

49. Ward JM and Rice JM. Naturally occurring and chemically induced brain tumors of rats and mice in carcinogenesis bioassays. Ann New York Acad Sci 1982; 381: 304–319.

50. Rice JM and Wilbourn JD. Tumors of the nervous system in evaluation of the Bradford Hill considerations and comparative analysis of weight of evidence. J Appl Toxicol 1986; 381: 304–319.

51. Thier R and Bolt HM. Carcinogenicity and genotoxicity of ethylene oxide: new aspects and recent advances. Crit Rev Toxicol 2000; 30: 595–608.
52. Greaves P. *Histopathology of preclinical toxicity studies*. 4th ed.. San Diego, CA: Elsevier B.V., 2012, pp. 33813–43866. 343-414.

53. Nakazawa M, Tawaratani T, Uchimoto H, et al. Spontaneous neoplastic lesions in aged Sprague-Dawley rats. *Exp Anim* 2001; 50: 99–103.

54. Haseman JK, Hailey JR and Morris RW. Spontaneous neoplasm incidences in Fischer 344 rats and B6C3F1 mice in two-year carcinogenicity studies: a national toxicology program update. *Toxicologic Pathol* 1998; 26: 428–441.

55. Rudmann D, Cardiff R, Chouinard L, et al. Proliferative and nonproliferative lesions of the rat and mouse mammary, zymbals, preputial, and clitoral glands. *Toxicologic Pathol* 2012; 40: 7S–39S.

56. Snellings W, Weil CS and Maronpot RR. A two-year inhaled study of the carcinogenic potential of ethylene oxide in Fischer 344 rats*1. *Toxicol Appl Pharmacol* 1984; 75: 105–117.

57. European Chemicals Agency (ECHA) Committee for Risk Assessment (RAC) and Scientific Committee on Occupational Exposure Limits (SCOEL). *Final report. Joint task force on scientific aspects and methodologies related to the exposure of chemicals at the workplace*, 2017. <https://echa.europa.eu/documents/10162/13579/jtf_opinion_task_2_en.pdf#db8a9a3a-4aa7-601b-bb53-81aee9f3145> (accessed 5 November 2020).

58. Kobets T and Williams GM. Review of the evidence for thresholds for DNA-reactive and epigenetic experimental chemical carcinogens. *Chemico-Biol Interact* 2019; 301: 88–111.

59. Kirman CR, Gargas ML, Marsh GM, et al. Cancer doresponse assessment for acrylonitrile based upon rodent brain tumor incidence: use of epidemiologic, mechanistic, and pharmacokinetic support for nonlinearity. *Regul Toxicol Pharmacol* 2005; 43: 85–103.

60. Ahmed AE, Jacob S and Ghanayem BI. Comparative disposition of acrylonitrile and methacrylonitrile: Quantitative whole-body autoradiographic studies in rats. *Toxicol Sci* 1996; 33: 49–59.

61. Kedderis GL, Batra R, Held SD, et al. Rodent tissue distribution of 2-cyanoethylene oxide, the epoxide metabolite of acrylonitrile. *Toxicol Lett* 1993; 69: 25–30.

62. Friedman M, Cavins JF and Wall JS. Relative nucleophilic reactivities of amino groups and mercaptide ions in adduction reactions with α,β-unsaturated compounds1,2. *J Am Chem Soc* 1965; 87: 3672–3682.

63. Kedderis GL and Batra R. Species differences in the hydrolysis of 2-cyanoethylene oxide, the epoxide metabolite of acrylonitrile. *Carcinogenesis* 1993; 14: 685–689.

64. Kedderis GL, Batra R and Turner MJ. Conjugation of acrylonitrile and 2-cyanoethylene oxide with hepatic glutathione. *Toxicol Appl Pharmacol* 1995; 135: 9–17.

65. Tardif R, Talbot D, Gérin M, et al. Urinary excretion of mercapturic acids and thiocyanate in rats exposed to acrylonitrile: influence of dose and route of administration. *Toxicol Lett* 1987; 39: 255–261.

66. Pilon D, Roberts AE and Rickert DE. Effect of glutathione depletion on the irreversible association of acrylonitrile with tissue macromolecules after oral administration to rats. *Toxicol Appl Pharmacol* 1988; 95: 311–320.

67. Nerland DE, Cai J, Pierce WM, et al. Covalent binding of acrylonitrile to specific rat liver glutathione S-transferases in vivo. *Chem Res Toxicol* 2001; 14: 799–806.

68. Leng G and Lewalter J. Polymorphism of glutathione S-transferases and susceptibility to acrylonitrile and dimethylsulfate in cases of intoxication. *Toxicol Lett* 2002; 134: 209–217.

69. Thier R, Balkenhol H, Lewalter J, et al. Influence of polymorphisms of the human glutathione transferases and cytochrome P450 2E1 enzyme on the metabolism and toxicity of ethylene oxide and acrylonitrile. *Mutat Research/Fundamental Mol Mech Mutagenesis* 2001; 482: 41–46.

70. Kedderis GL, Batra R and Koop DR. Epoxidation of acrylonitrile by rat and human cytochromes P450. *Chem Res Toxicol* 1993; 6: 866–871.

71. Roberts AE, Lacy SA, Pilon D, et al. Metabolism of acrylonitrile to 2-cyanoethylene oxide in F344 rat liver microsomes, lung microsomes, and lung cells. *Drug Metabol Dispos Biol Fate Chem* 1989; 17: 481–486.

72. Burk LT, Sanchez IM, Ahmed AE, et al. Comparative metabolism and disposition of acrylonitrile and methacrylonitrile in rats. *Arch Toxicol* 1994; 68: 611.

73. Fennell TR, Kedderis GL and Sumner SCJ. Urinary metabolites of [1,2,3-13C]acrylonitrile in rats and mice detected by carbon-13 nuclear magnetic resonance spectroscopy. *Chem Res Toxicol* 1991; 4: 678–687.

74. Sumner SCJ, Fennell TR, Moore TA, et al. Role of cytochrome P450 2E1 in the metabolism of acrylamide and acrylonitrile in mice. *Chem Res Toxicol* 1999; 12: 1110–1116.

75. Roberts AE, Kedderis GL, Turner MJ, et al. Species comparison of acrylonitrile epoxidation by microsomes from mice, rats and humans: relationship to epoxide concentrations in mouse and rat blood. *Carcinogenesis* 1991; 12: 401–404.

76. Abreu ME and Ahmed AE. Metabolism of acrylonitrile to cyanide. In vitro studies. *Drug Metab Disposition: Biol Fate Chemicals* 1980; 8: 376–379.

77. Chanas B, Wang H and Ghanayem BI. Differential metabolism of acrylonitrile to cyanide is responsible for the greater sensitivity of male vs female mice: role of CYP2E1 and epoxide hydrolases. *Toxicol Appl Pharmacol* 2003; 193: 293–302.

78. Elhadri L, Chanas B and Ghanayem B. Comparative metabolism of methacrylonitrile and acrylonitrile to cyanide using cytochrome P4502E1 and microsomal epoxide hydrolase-null mice. *Toxicol Appl Pharmacol* 2005; 205: 116–125.

79. Suhua W, Rongzhu L, Wenrong X, et al. Induction or inhibition of cytochrome P450 2E1 modifies the acute toxicity of...
acrylonitrile in rats: biochemical evidence. Arch Toxicol 2010; 84: 461–469.
80. Thier R, Lewalter J, Selinski S, et al. Possible impact of human CYP2E1 polymorphisms on the metabolism of acrylonitrile. Toxicol Lett 2002; 128: 249–255.
81. Nasralla SN, Ghoneim AI, Khalifa AE, et al. Lactoperoxidase catalyzes in vitro activation of acrylonitrile to cyanide. Toxicol Lett 2009; 191: 347–352.
82. Guengerich FP, Geiger LE, Hogy LL, et al. In vitro metabolism of acrylonitrile to 2-cyanoethylene oxide, reaction with glutathione, and irreversible binding to proteins and nucleic acids. Cancer Res 1981; 41: 4925–4933.
83. Ahmed AE and Patel K. Acrylonitrile: in vivo metabolism in rats and mice. Drug Metab Disposition: Biol Fate Chemicals 1981; 9: 219–222.
84. Sandberg EC and Slanina P. Distribution of [1-14C] acrylonitrile in rat and monkey. Toxicol Lett 1980; 6: 187–191.
85. Peter H and Bolt HM. Irreversible protein binding of acrylonitrile. Xenobiotica 1981; 11: 51–56.
86. Ahmed AE, Farooqui MYH, Upreti RK, et al. Comparative toxicokinetics of 2,3-14C- and 1-14C-acrylonitrile in the rat. J Appl Toxicol 1983; 3: 39–47.
87. Young J, Slauler R and Karbowksi R. Report. Midland, MI: Toxicology Research Laboratory of Dow Chemical Company, 1977. The pharmacokinetic and metabolism profile of 14C-acrylonitrile given to rats by three routes
88. Kedderis GL, Sumner SCJ, Held SD, et al. Dose-dependent urinary excretion of acrylonitrile metabolites by rats and mice. Toxicol Appl Pharmacol 1993; 120: 288–297.
89. Jacob S. Effect of route of administration on the disposition of acrylonitrile: quantitative whole-body autoradiographic study in rats. Pharmacol Res 2003; 48: 479–488.
90. Snyder R. Ethel Browning’s toxicity and metabolism of industrial solvents. 2nd ed., Vol. II. Amsterdam-New York-Oxford: Elsevier, 1990, p. 314. Nitrogen and Phosphorus Solvents.
91. Lewis RS. Sax’s dangerous properties of industrial materials. 11th ed., Hoboken, NJ: Lewis Information Systems, Inc. John Wiley & Sons, Inc., 2004, p. 72.
92. Ghanayem BI, Farooqui MYH, Elshabrawy O, et al. Assesment of the acute acrylonitrile-induced neurotoxicity in rats. Neurotoxicology and Teratology 1991; 13: 499–502.
93. Wang H, Chanas B and Ghanayem BI. Cytochrome P450 2E1 (CYP2E1) is essential for acrylonitrile metabolism to cyanide: comparative studies using CYP2E1-null and wild-type mice. Drug Metab Disposition 2002; 30: 911–917. DOI: 10.1124/dmd.30.8.911.
94. Campian EC, Cai J and Benz FW. Acrylonitrile irreversibly inactivates glyceraldehyde-3-phosphate dehydrogenase by alkylating the catalytically active cysteine 149. Chemico-Biol Interact 2002; 140: 279–291.
95. Esmat A, Eldemerdash E, Elmesallamy H, et al. Toxicity and oxidative stress of acrylonitrile in rat primary glial cells: preventive effects of N-acetylcysteine. Toxicol Lett 2007; 171: 111–118.
96. Wang Z, Zhou S, Pu X, et al. Acrylonitrile induced alterations in mitochondrial biogenesis and bioenergetics in cultured rat astrocytes. Int J Cancer Stud Res 2015; 4: 75–81.
97. Campian EC and Benz FW. The acute lethality of acrylonitrile is not due to brain metabolic arrest. Toxicology 2008; 253: 104–109.
98. Ghanayem BI, Boor PJ and Ahmed AE. Acrylonitrile-induced gastric mucosal necrosis: role of gastric glutathione. J Pharmacol Exp Therap 1985; 232: 570–577.
99. Ahmed AE, Nouraldeen AM, Abdel-Rahman SZ, et al. Role of glutathione modulation in acrylonitrile-induced gastric DNA damage in rats. Arch Toxicol 1996; 70: 620–627.
100. Szabo S, Bailey KA, Boor PJ, et al. Acrylonitrile and tissue glutathione: differential effect of acute and chronic interations. Biochem Biophysical Res Commun 1977; 79: 32–37.
101. Benz FW, Nerland DE, Corbett D, et al. Biological markers of acute acrylonitrile intoxication in rats as a function of dose and time. Toxicol Sci 1997; 36: 141–148.
102. Szabo S, Gallagher GT, Silver EH, et al. Subacute and chronic action of acrylonitrile on adrenals and gastrointestinal tract: biochemical, functional and ultrastructural studies in the rat. J Appl Toxicol 1984; 4: 131–140.
103. Ghanayem B. Effects of the carcinogen, acrylonitrile, on forestomach cell proliferation and apoptosis in the rat: comparison with methacrylonitrile. Carcinogenesis 1997; 18: 675–680.
104. Gagnaire F, Marignac B and Bonnet P. Relative neurotoxological properties of five unsaturated aliphatic nitriles in rats. J Appl Toxicol 1998; 18: 25–31.
105. Humiston C, Frauson LO, Quast JF, et al. A 90-day oral toxicity study incorporating acrylonitrile in the drinking water of rats. Report. Midland, MI: Toxicology Research Laboratory of Dow Chemical Company, 1975.
106. Murray FJ, Schwetz BA, Nitschke KD, et al. Teratogenicity of acrylonitrile given to rats by gavage or by inhalation. Food Cosmetics Toxicol 1978; 16: 547–551.
107. Nemec MD, Kirkpatrick DT, Sherman J, et al. Two-generation reproductive toxicity study of inhaled acrylonitrile vapors in CrI:CD(SD) rats. Int J Toxicol 2008; 27: 11–29.
108. Friedman MA and Beliles RP. Three-generation reproduction study of rats receiving acrylonitrile in drinking water. Toxicol Lett 2002; 132: 249–261.
109. Kobets T, Iatropoulos MJ and Williams GM. Mechanisms of DNA-reactive and epigenetic chemical carcinogens: applications to carcinogenicity testing and risk assessment. Toxicol Res 2018; 8: 123–145.
110. Preston RJ and Williams GM. DNA-reactive carcinogens: mode of action and human cancer hazard. Crit Rev Toxicol 2005; 35: 673–683.
111. Gladovic M, Spaninger E and Bren U. Nucleic bases alkylation with acrylonitrile and cyanoethylene oxide: a computational study. Chem Res Toxicol 2018; 31: 97–104.
112. Hogy LL and Guengerich FP. In vivo interaction of acrylonitrile and 2-cyanoethylene oxide with DNA in rats. Cancer Res 1986; 46: 3932–3938.

113. Solomon JJ and Segal A. Direct alkylation of calf thymus DNA by acrylonitrile. Isolation of cyanoethyl adducts of guanine and thymine and carboxyethyl adducts of adenine and cytosine. Environ Health Perspect 1985; 62: 227–230.

114. Solomon JJ and Segal A. DNA adducts of propylene oxide and acrylonitrile epoxide: hydrolytic deamination of 3-alkyl-dCyd to 3-alkyl-dUrd. Environ Health Perspect 1989; 81: 19–22.

115. Solomon JJ, Singh US and Segal A. In vitro reactions of 2-cyanoethylene oxide with calf thymus DNA. Chemico-Biol Interact 1993; 88: 115–135.

116. Whysner J, Ross PM, Conaway CC, et al. Evaluation of possible genotoxic mechanisms for acrylonitrile tumorigenicity. Regul Toxicol Pharmacol 1998; 27: 217–239.

117. Farooqui MYH and Ahmed AE. In vivo interactions of acrylonitrile with macromolecules in rats. Chemico-Biol Interact 1983; 47: 363–371.

118. Farooqui MYH and Ahmed AE. The effects of acrylonitrile on hemoglobin and red cell metabolism. J Toxicol Environ Health 1983; 12: 695–707.

119. Pilon D, Roberts AE and Rickert DE. Effect of glutathione depletion on the uptake of acrylonitrile vapors and on its irreversible association with tissue macromolecules. Toxicol Appl Pharmacol 1988; 95: 265–278.

120. Whysner J, Stewart RE 3rd, Chen D, et al. Formation of 8-oxodeoxyguanosine in brain DNA of rats exposed to acrylonitrile. Arch Toxicol 1998; 72: 429–438.

121. Abdel-Rahman SZ, Nouraldeen AM and Ahmed AE. Molecular interaction of [2,3-14C] acrylonitrile with DNA in gastric tissue of rat. J Biochem Toxicol 1994; 9: 191–198.

122. Ahmed AE, Abdel-Azziz AH, Abdel-Rahman SZ, et al. Pulmonary toxicity of acrylonitrile: covalent interaction and effect on replicative and unscheduled DNA synthesis in the lung. Toxicology 1992; 76: 1–14.

123. Ahmed AE, Abdel-Rahman SZ and Nour Deen AM-A. Acrylonitrile interaction with testicular DNA in rats. J Biochem Toxicol 1992; 7: 5–11.

124. Peter H, Schwarz M, Mathiasch B, et al. A note on synthesis and reactivity towards DNA of glycidonitrile, the epoxide of acrylonitrile. Carcinogenesis 1983; 4: 235–237.

125. Peter H, Appel KE, Berg R, et al. Irreversible binding of acrylonitrile to nucleic acids. Xenobiotica 1983; 13: 19–25.

126. Brown K, Dingley KH and Turteltaub KW. Accelerator mass spectrometry for biomedical research. Methods enzymol. Amsterdam, Netherlands: Elsevier, 2005, pp. 423–443.

127. Reddy MV and Randerath K. 32P-postlabeling assay for carcinogen-DNA adducts: nuclease P1-mediated enhancement of its sensitivity and applications. Environ Health Perspect 1987; 76: 41–47.

128. Benz FW, Nerland DE, Li J, et al. Dose dependence of covalent binding of acrylonitrile to tissue protein and globin in rats. Toxicol Sci 1997; 36: 149–156.

129. Duverger-van Bogaert M, Lambotte-Vandepaer M, Mercier M, et al. In vitro covalent binding of acrylonitrile to rat liver proteins. Toxicol Letters 1982; 13: 203–209.

130. Geiger LE, Hogy LL and Guengerich FP. Metabolism of acrylonitrile by isolated rat hepatocytes. Cancer Res 1983; 43: 3080–3087.

131. Küting B, Uter W and Drexler H. The association between self-reported acrylamide intake and hemoglobin adducts as biomarkers of exposure. Cancer Causes & Control 2007; 19: 273–281.

132. Schettgen T, Müller J, Fromme H, et al. Simultaneous quantification of haemoglobin adducts of ethylene oxide, propylene oxide, acrylonitrile, acrylamide and glycylamide in human blood by isotope-dilution GC/NCI-MS/MS. J Chromatogr B 2010; 878: 2467–2473.

133. Bader M and Wribitzer R. Follow-up biomonitoring after accidental exposure to acrylonitrile-Implications for protein adducts as a dose monitor for short-term exposures. Toxicol Lett 2006; 162: 125–131.

134. Osterman-Golkar SM, MacNeela JP, Tumer MJ, et al. Monitoring exposure to acrylonitrile using adducts with N-terminal valine in hemoglobin. Carcinogenesis 1994; 15: 2701–2707.

135. Léonard A, Gerber GB, Stecca C, et al. Mutagenicity, carcinogenicity, and teratogenicity of acrylonitrile. Mutat Research/Reviews Mutat Res 1999; 436: 263–283.

136. Recio L and Skopek TR. Mutagenicity of acrylonitrile and its metabolite 2-cyanoethylene oxide in human lymphoblasts in vitro. Mutat Research/Genetic Toxicol 1988; 206: 297–305.

137. Bouzyk E, Gradzka I, Iwaneiko T, et al. The response of LS178Y lymphoma sublines to oxidative stress: antioxidative defence, iron content and nuclear translocation of the p65 subunit of NF-kappaB. Acta Biochim Pol 2000; 47: 881–888.

138. Nakagawa Y, Toyoizumi T, Sui H, et al. In vivo comet assay of acrylonitrile, 9-aminoacridine hydrochloride monohydrate and ethanol in rats. Mutat Research/Genetic Toxicol Environ Mutagenesis 2015; 786–788: 104–113.

139. Cadet J and Douki T. Formation of UV-induced DNA damage contributing to skin cancer development. Photochemical Photobiological Sci 2018; 17: 1816–1841.

140. Kasai H. Analysis of a form of oxidative DNA damage, 8-hydroxy-2′-deoxyguanosine, as a marker of cellular oxidative stress during carcinogenesis. Mutat Research/Reviews Mutat Res 1997; 387: 147–163.

141. Klaunig JE and Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 2004; 44: 239–267.

142. Williams GM and Jeffrey AM. Oxidative DNA damage: endogenous and chemically induced. Regul Toxicol Pharmacol 2000; 32: 283–292.
143. McCarthy MM. Location, location, location: microglia are where they live. *Neuron* 2017; 95: 233–235.

144. Soulet D and Rivest S. Bone-marrow-derived microglia: myth or reality? *Curr Opin Pharmacol* 2008; 8: 508–518.

145. Kamendulis LM, Jiang J, Xu Y, et al. Induction of oxidative stress and oxidative damage in rat glial cells by acrylonitrile. *Carcinogenesis* 1999; 20: 1555–1560.

146. Jiang J, Xu Y and Klaunig JE. Induction of oxidative stress in rat brain by acrylonitrile (ACN). *Toxicol Sci* 1998; 46: 333–341.

147. Pu X, Kamendulis LM and Klaunig JE. Acrylonitrile-induced oxidative stress and oxidative DNA damage in male Sprague-Dawley rats. *Toxicol Sci* 2009; 111: 64–71.

148. Jacob S and Ahmed AE. Acrylonitrile-induced neurotoxicity in normal human astrocytes: Oxidative stress and 8-hydroxy-2′-deoxyguanosine formation. *Toxicol Meth Method* 2003; 13: 169–179.

149. Knight TR, Choudhuri S and Klaassen CD. Constitutive mRNA expression of various glutathione S-transferase isoforms in different tissues of mice. *Toxicol Sci* 2007; 100: 513–524.

150. Singh SV, Saunders MO, Moller PC, et al. Comparative studies on the isoenzymes of glutathione S-transferase of rat brain and other tissues. *Comp Biochem Physiol B: Comp Biochem* 1987; 86: 73–81.

151. Hamdy NM, Al-Abbasi FA, Alghamdi HA, et al. Role of neutrophils in acrylonitrile-induced gastric mucosal damage. *Toxicol Lett* 2012; 208: 108–114.

152. Pu X, Wang Z, Zhou S, et al. Protective effects of antioxidants on acrylonitrile-induced oxidative stress in female F344 rats. *Environ Toxicol* 2016; 31: 1808–1818.

153. Poirier M, Fournier M, Brousseau P, et al. Effects of volatile aromatics, aldehydes, and phenols in tobacco smoke on viability and proliferation of mouse lymphocytes. *J Toxicol Environ Health A* 2002; 65: 1437–1451.

154. Hamada FM, Abdel-Aziz AH, Abd-Allah AR, et al. Possible functional immunotoxicity of acrylonitrile (VCN). *Pharmacol Res* 1998; 37: 123–129.

155. Kamendulis LM, Jiang J, Zhang H, et al. The effect of acrylonitrile on gap junctional intercellular communication in rat astrocytes. *Cell Biol Toxicol* 1999; 15: 173–183.

156. Li XJ, Li B, Huang JS, et al. Effects of acrylonitrile on lymphocyte lipid rafts and RAS/MAPK/ERK signaling pathways. *Genet Mol Res* 2014; 13: 7747–7756.

157. Nelson PT, Soma LA and Lavi E. Microglia in diseases of the central nervous system. *Ann Med* 2002; 34: 491–500.

158. Roesch S, Rapp C, Dettling S, et al. When immune cells turn bad-tumor-associated microglia/macrophages in glioma. *Int J Mol Sci* 2018; 19: 436.

159. Melnick RL, Sills RC, Roycroft JH, et al. Isoprene, an endogenous hydrocarbon and industrial chemical, induces multiple organ neoplasia in rodents after 26 weeks of inhalation exposure. *Cancer Res* 1994; 54: 5333–5339.

160. National Toxicology Program (NTP). *Toxicology and carcinogenesis studies of benzene (CAS No. 71-43-2) in F344/N rats and B6C3F1 mice (gavage studies).* Research Triangle Park, NC: Public Health Service, US Department of Health and Human Services. National Institute of Environmental Health Sciences, 1986, pp. 1–277.

161. National Toxicology Program (NTP). *Toxicology and carcinogenesis studies of nitromethane (CAS No. 75-52-5) in F344/N rats and B6C3F1 mice (inhalation studies).* Research Triangle Park, NC: Public Health Service, US Department of Health and Human Services. National Institute of Environmental Health Sciences, 1997, pp. 1–289.

162. Payne AP. The hardierian gland: a tercentenary review. *J Anat* 1994; 185 (Pt 1); 1–49.

163. Williams GM and Iatropoulos MJ. Alteration of liver cell function and proliferation: differentiation between adaptation and toxicity. *Toxicologic Pathol* 2002; 30: 41–53.

164. Proctor DM, Suh M, Chappell G, et al. An Adverse Outcome Pathway (AOP) for forestomach tumors induced by non-genotoxic initiating events. *Regul Toxicol Pharmacol* 2018; 96: 30–40.

165. Williams GM and Iatropoulos MJ. Evaluation of potential human carcinogenicity of the synthetic monomer ethyl acrylate. *Regul Toxicol Pharmacol* 2009; 53: 6–15.

166. Hughes MF. Arsenic toxicity and potential mechanisms of action. *Toxicol Lett* 2002; 133: 1–16.

167. Kinoshita A, Wanibuchi H, Imaoka S, et al. Formation of 8-hydroxydeoxyguanosine and cell-cycle arrest in the rat liver via generation of oxidative stress by phenobarbital: association with expression profiles of p21WAF1/Cip1, cyclin D1 and Ogg1. *Carcinogenesis* 2002; 23: 341–349.

168. Umemura T, Kai S, Hasegawa R, et al. Pentachlorophenol (PCP) produces liver oxidative stress and promotes but does not initiate hepatocarcinogenesis in B6C3F1 mice. *Carcinogenesis* 1999; 20: 1115–1120.

169. ACarozzi V, Marmiroli P and Cavaletti G. The role of oxidative stress and anti-oxidant treatment in platinum-induced peripheral neurotoxicity. *Curr Cancer Drug Targets* 2010; 10: 670–682.

170. Thier R, Lewalter J and Bolt HM. Species differences in acrylonitrile metabolism and toxicity between experimental animals and humans based on observations in human accidental poisonings. *Arch Toxicol* 2000; 74: 184–189.

171. Sweeney LM. Physiologically based pharmacokinetic model parameter estimation and sensitivity and variability analyses for acrylonitrile disposition in humans. *Toxicol Sci* 2003; 71: 27–40.

172. Proctor DM, Gatto NM, Hong SJ, et al. Mode-of-action framework for evaluating the relevance of rodent forestomach tumors in cancer risk assessment. *Toxicol Sci* 2007; 98: 313–326.

173. Wester PW and Kroes R. Forestomach carcinogens: pathology and relevance to man. *Toxicologic Pathol* 1988; 16: 165–171.

174. Hulette CM. Microglioma, a histiocytic neoplasm of the central nervous system. *Mod Pathol Official J United States Can Acad Pathol* 1996; 9: 316–319.
175. Sasaki A. Microglia and brain macrophages: an update. *Neuropathology* 2016; **37**: 452–464.

176. Wirsching H-G, Galanis E and Weller M. Glioblastoma. *Handbook Clin Neurol* 2016; **134**: 381–397.

177. Mathews A, Ohsawa K, Buckland ME, et al. Microglioma in a child - a further case in support of the microglioma entity and distinction from histiocytic sarcoma. *Clin Neuropathol* 2016; **35**: 302–313.

178. Collins JJ and Strother DE. CNS tumors and exposure to acrylonitrile: inconsistency between experimental and epidemiology studies. *Neuro-Oncology* 1999; **1**: 221–230.

179. Abbott NJ. Astrocyte-endothelial interactions and blood-brain barrier permeability*. J Anat* 2002; **200**: 629–638.

180. Banks WA. Mouse models of neurological disorders: a view from the blood-brain barrier. *Biochim Biophys Acta (Bba) - Mol Basis Dis* 2010; **1802**: 881–888.

**Nomenclature**

| BMD  | benchmark dose |
|------|----------------|
| CEO  | 2-cyanoethylenoxide |
| CSF  | cancer slope factor |
| F344 | Fischer 344 rat strain |
| GSH  | reduced glutathione |
| GST  | glutathione s-transferase |
| LOAEL | lowest-observed-adverse-effect level |
| MoA  | mechanism of action |
| NOAEL | no-observed-adverse-effect level |
| SD   | Sprague-Dawley rat strain |
| WoE  | weight of evidence |